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ABSTRACT 
The cryopreservation of cells and tissue engineered constructs is determined by multiple factors, such as possible cellular 
damages due to mass and heat transfer during the freezing and thawing process. It is assumed that the utilization of 
cryobags improves the heat transfer during freezing and thawing and is therefore superior in comparison to currently 
applied cryovials and multiwell plates. Therefore, we have analysed the cryopreservation of cell-seeded electrospun 
polycaprolactone/polylactide scaffolds within cryobags. Additionally, the performance of four different cryoprotective 
agents was analysed, which included 10% (v/v) dimethyl sulfoxide and 10% (v/v) ethylene glycol as separately applied 
agents as well as their combination with 0.3 M sucrose. The samples were frozen in in-house made cryobags with a 
controlled rate freezer. The cell viability was analysed by fluorescence microscopy before freezing and after thawing. The 
results show, that the application of cryobags in combination with 10% (v/v) ethylene glycol can have a positive impact 
onto the cell viability. 
Keywords: cryopreservation, cryobags, tissue engineered constructs, cryoprotective agents, cell viability 
INTRODUCTION 
In recent years, the development and analysis of tissue 
engineered constructs (TECs) has increased within 
regenerative medicine [1], as TECs hold the potential 
application as substitutes for the regeneration of tissue 
defects [2-4]. Especially the development of suitable 
scaffolds is of upmost importance. A desired cell type is 
seeded onto the scaffolds’ surface and proliferates in 
vitro. Finally, the scaffolds can be applied to the 
defective site [5]. Regarding this methodical approach, 
the electrospinning method is a widely utilized and 
versatile scaffold fabrication technique. Thereby a thin 
fibre is formed out of a polymeric solution due to the 
application of an electric field and is collected. 
Dependent upon the set process parameters, the fibre 
mats can be tailored [6-8]. 
However, a remaining challenge is the long-term storage 
of biological products. Currently, the frequently applied 
hypothermic preservation methods do not allow a 
sufficient long-term storage [9, 10]. Therefore, new 
preservation methods have to be evolved in order to 
ensure a sufficient availability of TECs. A possible 
alternative to overcome these limitations in storing 
duration of TECs is cryopreservation. This method 
enables the storage at sub-zero temperatures, thus 
reducing metabolic activity and increasing the shelf-life. 
It has to be noted though, that also this preservation 
method is influenced by various parameters [11, 12]. 
Due to the cryogenic conditions as well as due to 
multiple parameters, such as mass and heat transfer 
during freezing and thawing, cellular injury can occur 
[13, 14]. A possibility to enhance the heat transfer is the 
utilization of cryobags since they possess a comparably 
flatter structure. However, different cell types have 
already been cryopreserved within cryobags [15-19] but 
to the field of TECs this method is fairly new and the 
various influences of the preservation method onto the 
specimen have to be investigated further.  
Therefore, the aim of this study was to analyse the 
viability of cryopreserved cells, seeded onto electrospun 
scaffolds and stored within cryobags as well as the 
impact of different cryoprotective agents (CPAs). The 
results were compared to previous studies of our group, 
in which the cell-seeded TECs were cryopreserved 




Electrospinning and sample preparation  
The scaffolds were fabricated by electrospinning. 
Polycaprolactone (PCL, from Aldrich) with an average 
Mn of 80,000 and polylactic acid (PLLA, from 
Natureplast) with an average Mn of 150,000 were 
dissolved in 2.2.2-trifluoroethanol (TFE, from abcr) 
with a mass concentration ratio of 100:50 (mg ml-1: 
mg ml-1). The solution homogenized for 24 h before 
electrospinning.  
Electrospinning was performed in a horizontal 
orientation. The polymer solution was ejected through a 
metallic needle (0,8 mm inner diameter, from B. Braun) 
at an applied flow rate of 3 ml h-1 and a voltage of 15 kV 
with a spinning distance of 21 cm and a duration of 
100 min. The fibres where collected on a rotating drum 
collector at 220 rpm. 
Finally, the electrospun fibre mats were UV sterilized on 
each side for a duration of 15 min and punched into 
16 mm scaffolds.  
Cryopreservation 
SaOS-2 cells were utilized for the viability analysis. The 
cells were seeded onto the surface of the electrospun 
scaffolds at a density of 5×104 cells cm-2 and 
proliferated for 3 days under physiological conditions in 
an incubator before cryopreservation. Control samples 
were analysed before preservation. 
Prior to cryopreservation, the samples were loaded with 
different CPA-solutions (Table 1) at 4°C for 10 min, 
before being transferred into cryobags (ProfiCook) and 
cooled in a controlled rate freezer (Planer) at 1 K min-1 
to -100°C, then being plunged into liquid nitrogen and 
stored at -140°C in a cryogenic freezer (Fisher 
Scientific). Every cryobag contained four identical 
TECs and was frozen in our previously described “in-
air” method [20]. 
After low temperature storage the TECs were rapidly 
thawed in a water bath at 37°C for 15 s. The samples 
were placed in multiwell plates (TPP) containing warm 
culture medium and incubated for 5 min. The medium 
was refreshed and the samples were cultured for 24 h 
before the viability analysis. 
Cell viability analysis 
The cell viability was analysed by live-dead assay with 
a fluorescence microscope (Zeiss). Prior to staining, the 
samples were washed twice in 2 ml PBS before and after 
applying the staining solution. Calcein AM (Biotium) 
and Ethidium Homodimer-1 (Aldrich) served as 
fluorescence dyes. Images were taken in a z-stack mode 
and the cell viability was analysed with the ImageJ 
software (NIH). 
Table 1: Four different CPA solutions were prepared. 
Dimethyl sulfoxide (DMSO, from Roth) and ethylene 
glycol (EG, from Aldrich) with and without sucrose 
(Suc, from Aldrich). All solutions contained 20% fetal 
bovine serum (FBS, from Biochrom) and Dulbecco's 
Modified Eagle Medium (DMEM, from Biochrom). 
Values in percent are v/v. 
Solution DMSO EG Suc 
DMSO 10% - - 
DMSO+Suc 10% - 0.3 M 
EG - 10% - 
EG+Suc - 10% 0.3 M 
Data analysis and statistics 
All data were collected from four individual 
experiments and are represented as the mean and 
standard deviation. 
RESULTS 
Cell viability analysis 
Two different morphologies of attached cells were 
present on the TECs surface. The dominant cell 
morphology had a round shape, but also stretched cells 
were visible. Additionally, the cells were also partially 
aligned in fibre orientation. It was discovered, that the 
cell morphology was not affected by the 
cryopreservation process. 
On day 3, a viability of 97% ± 2% could be obtained for 
the cultivated cell-seeded TECs prior to 
cryopreservation, serving as a control.  
After the cryopreservation and recultivation, the post-
thaw cell viability was influenced by the applied CPA-
solution. In this study, the highest cell viability with a 
mean value of 80% ± 11% could be obtained with 10% 
(v/v) EG as well as its combination with 0,3 M sucrose 
(79% ± 7%), respectively. In comparison, the 
application of 10% (v/v) DMSO yielded in a post-thaw 
viability of 77% ± 6%. Combining DMSO with sucrose 
lead to a viability of 78% ± 7%.  
It has to be noted, that the post-thaw viability can be 
influenced by rupture of the cryobags during the 
thawing procedure and will yield in a reduced viability.  
Generally, the trend of viability also corresponds with 
the number of total cells. This indicates that the highest 
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post-thaw cell number was present for a CPA-solution 
containing 10% (v/v) EG as well as its combination with 
sucrose.  
Figure 1: Post-thaw viability. n=64 (1n=44, 2n=60) 
Figure 2: Representative live-dead images. Control 
(left) and 10% (v/v) EG (right). Scale bars are 150 µm. 
DISCUSSION 
Within the field of cryobiology, the application of CPAs 
is of vital importance in order to achieve a sufficient 
post-thaw viability. In this study, all analysed CPA-
solutions enabled a viability of >70%. Furthermore, the 
highest viability was obtained for solutions containing 
10% (v/v) EG. Since the applied concentrations of 
DMSO and EG are identical and the membrane 
permeation is known to dependent upon the molecular 
weight of the CPA [21], this could provide an 
explanation for the obtained viability. Therefore, EG 
could provide a suitable alternative to DMSO, which is 
known to induce a toxic effect above 4°C [22]. 
However, possible toxic effects of EG on the cells 
should still be elaborated in future. Furthermore, sucrose 
only had a subdominant effect on the viability. This 
correlates with previous findings [23]. It is also known, 
that the diffusion rate of sucrose into tissue is lower than 
other CPAs such as DMSO [24].  
The utilization of cryobags holds a promising approach 
to increase the post-thaw cell viability. Compared to 
current cryopreservation methods in cryovials or in 
multiwell plates, the cryobags possess the advantage of 
being customizable to the individual volume and 
geometry of each sample. It has to be noted though, that 
the cryobag material can be potentially susceptible to 
rupture during the thawing process and can cause cell 
loss, as discovered in our study. The material failure has 
also been previously described by other authors [25, 26]. 
In this current study, a possibility to overcome this 
limitation was achieved be thawing in a warm PBS bath. 
Previously our group also cryopreserved TECs within 
multiwell plates. A comparison indicates that a higher 
post-thaw viability could be obtained within the 
cryobags (data not shown). Therefore, cryobags seem to 
improve the heat transfer and thus enable an enhanced 
cryopreservation outcome.  
CONCLUSIONS 
The current cryopreservation methods enable the long-
term storage of cell-seeded TECs. In view of the utilized 
CPAs, 10% (v/v) EG offers a suitable alternative to the 
commonly applied but more toxic DMSO. Also, the 
application of sucrose can have a beneficial impact onto 
the cell viability. Regarding the storage method of 
TECs, cryobags improve the post-thaw cell viability 
compared to multiwell plates, and therefore represent an 
alternative preservation method.  
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ABSTRACT 
Solid triglyceride nanoparticles are under intensive investigation as drug delivery systems. In the solid state, triglycerides 
exist in three polymorphic modifications which differ from each other in their physicochemical properties. Thus, it is 
particularly important to know the influence of parameters affecting the polymorphic behavior of the solid triglyceride 
nanoparticles to get a stable product with defined physicochemical properties over an appropriate storage time. This study 
investigated the effect of subsequent addition of SDS to tripalmitin nanoparticles, which had been stabilized with partially 
hydrolyzed poly(vinyl alcohol) (PVA). The polymorphic behavior was characterized with DSC and X-ray diffraction 
over a storage time of 28 d at 20 °C. A faster transition into more stable polymorphic modifications was observed after 
the addition of SDS to the nanoparticles.  
Keywords: triglycerides, polymorphism, PVA, SDS 
INTRODUCTION 
Nanoparticles of solid lipids were first investigated by 
Speiser et al. [1986] and further developed as potential 
drug delivery systems for poorly water-soluble drugs 
[Bunjes, 2010]. The physicochemical properties of the 
nanoparticles depend on, e.g., the used matrix lipid, the 
stabilizer as well as additional substances. As matrix 
lipid e.g., triglycerides can be used. Triglycerides are 
polymorphic substances and mainly occur in three 
different polymorphic modifications. These 
modifications differ from each other in their 
physicochemical properties due to a different 
arrangement of the triglyceride molecules [Chapman, 
1962]. According to Ostwald’s step rule, triglycerides 
crystallize in the metastable α-modification and undergo 
time- and temperature dependent monotropic transitions 
into the stable β-modification, sometimes via the β’-
modification. The different physicochemical properties 
of the solid triglyceride particles when present in 
different crystal modifications might influence the drug 
loading capacity as well as the physical stability of the 
dispersion. Therefore, it is essential to understand the 
effect of additives to obtain a stable product over the 
necessary shelf life. In this study, tripalmitin was used 
as matrix lipid and the nanoparticles were stabilized 
with partially hydrolyzed poly(vinyl alcohol). SDS was 
added to the dispersions to investigate the effect on the 
physicochemical behavior of the PVA-stabilized 
nanoparticles and to get further information about how 
PVA interacts with the matrix lipid. 
RESEARCH CONCEPT 
For this study, dispersions consisting of 5 % tripalmitin 
(Dynasan® 116, Condea), 5, 7.5, 10 or 15 % Kuraray 
Poval 3-83 (Kuraray Europe GmbH) and bidestilled 
water, in which the PVA was dissolved, were prepared 
by high pressure melt homogenization (all 
concentrations w/w). To each dispersion 0.1 or 0.3 % 
SDS (Carl Roth GmbH) was added after the 
homogenization procedure as described in this section. 
A dispersion without SDS was used as reference.  
First, the lipid and the aqueous phase were heated at 
approx. 80 °C separately. Afterwards, both phases were 
combined and pre-homogenized with an ultra-turrax 
(IKA T25 digital Ultra-Turrax; SN25-10G, IKA-Werke) 
at 13.000 rpm for 4 min. The premix was homogenized 
in a preheated Microfluidizer M110-P instrument 
(Microfluidics) for 10 cycles at 800 bar. The hot 
dispersion was divided into three parts. To two parts 
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SDS in the respective concentration was added as a 
powder in the heat and dissolved under gentle shaking. 
In a following cooling step, the matrix lipid was allowed 
to crystallize in an ice-water bath.  
The particle size was measured with a Zetasizer Nano 
ZSP instrument (Malvern) at 25 °C and an angle of 
173 °. The dispersions were diluted with purified and 
particle free water. The z-average diameter and PDI 
were given as mean of three measurements of 5 min 
each after 5 min of equilibration. 
Differential scanning calorimetry (DSC) measurements 
were performed in a DSC 3 Stare System with a full 
range sensor (FRS 6+) and a sample robot (Mettler 
Toledo GmbH). 15 µl of the dispersions were accurately 
weighed into aluminum crucibles that were cold sealed. 
The samples were heated from 0 to 85 °C with a heating 
rate of 10 K/min, held at that temperature for 10 min and 
cooled to -5 °C with a cooling rate of 10 K/min. As a 
reference, an empty aluminum pan was used, and all 
measurements were performed under nitrogen purge. 
The enthalpies obtained as areas under the curve upon 
evaluation were normalized for the weight of the 
samples. 
The melting enthalpies were used to approximate the 
formation of particles in the stable β-modification. 
X-ray measurements were performed with a small- and
wide-angle X-ray diffraction setup (SAXSess mc²,
Anton Paar) equipped with a copper radiation source
(λ = 0.154 nm) and a CCD detector as well as a Mythen
detector. The sample was measured in a quartz capillary
sample holder in 20 runs of 60 s each at 20 °C.
Background subtraction and desmearing was performed
for all diffractograms.
RESULTS 
All dispersions had a milky white appearance. However, 
the more PVA was used as emulsifier, the more 
transparent was the dispersion. After the addition of 
SDS, the appearance did not change. The z-average and 
PDI values were 75 - 100 nm or 0.10 - 0.20, 
respectively, and depended on two parameters. First, the 
more PVA was used, the smaller were the particles. 
Second, with addition of SDS the z-average and PDI 
values increased. This effect on the particle size was less 
pronounced when more PVA was used in the original 
dispersion. 
During cooling the sample in the DSC, the 
crystallization temperature increased with the addition 
of SDS from approx. 25 to 28 °C for tripalmitin 


















Figure 1: Wide angle X-ray diffractograms of 
tripalmitin nanoparticles. The composition of the 
dispersions was 5 % tripalmitin, 5 % Kuraray Poval 3-
83 and 0, 0.1 or 0.3 % SDS, respectively. The 
diffractograms were recorded after 0, 1, 4, 7, 14, 21 and 
28 d of storage at 20 °C. 
nanoparticles, which were stabilized with 5 % PVA. 
Comparable to the effect on the particle size, the 
influence on the crystallization temperature also 
decreased with increasing total PVA concentration in 
the sample. In this case, the crystallization temperature 
was nearly constant at 22 °C for dispersions, which were 
stabilized with a total PVA-concentration of 15 %. 
After crystallization, all particles were present in the 
metastable α-modification, which was confirmed with 
DSC and X-ray measurements. According to the SAXS 
patterns, the triglyceride in the lipid particles was 
arranged with a reduced lamellarity. The SAXS signals 
increased over the storage time for all samples. The 
0.3 % SDS-containing sample displayed additional 
signals in the wide-angle scattering pattern at approx. 
14.2 and 16.8 nm-1 (fig. 1). During the observed period 
of storage, the matrix lipid underwent time-dependent 
polymorphic transitions into more stable modifications. 
This could be confirmed with DSC measurements, 
which showed an increased size of the melting event at 
higher temperatures after 28 d of storage. 
In contrast, there were no indications for the presence of 
particles in the β’-modification in the wide-angle range 
of the sample without SDS (fig. 1). These effects were 
also observed for the dispersions stabilized with higher 
concentrations of PVA or only 0.1 % additional SDS. 
DISCUSSION 
The addition of SDS to tripalmitin nanodispersions 
stabilized with partially hydrolyzed PVA had an 
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influence on their physicochemical behavior. It is 
known that PVA has a strong stabilizing effect on 
metastable polymorphic modifications in triglyceride 
nanoparticles [Rosenblatt et al., 2008]. The assumption 
in the present study was that the stronger the interaction 
between PVA and the matrix lipid, the lower is the 
crystallization temperature and the higher the stability of 
the metastable α-modification. The increase of the 
crystallization temperature with increasing SDS 
concentration might be an indication that the interaction 
between the matrix lipid and PVA is weakened in 
comparison to the reference dispersion without SDS.  
Another indication for the reduction of the interaction 
between the matrix lipid and the main emulsifier, PVA, 
is the more pronounced polymorphic transition into 
more stable modifications. The particles with SDS 
addition transformed more rapidly into the β’-
modification, which could be detected in the WAXS-
pattern in fig. 1 [Chapman, 1962].  
A possible cause of the observed phenomena might be 
an interaction between PVA and the additional SDS, 
which might influence the stabilization properties of 
PVA. It is supposed that SDS associates with PVA thus 
leading to a stretching of the polymer [Ramirez, 2020]. 
This could cause a more hydrophilic character of PVA. 
Consequently, the interaction between PVA and the 
matrix lipid would be reduced, which is reflected in the 
increasing crystallization temperature of the triglyceride 
nanoparticles. 
The higher the PVA concentration, the lower is the 
effect of SDS addition on the observed effects on the 
crystallization temperature as well as on the particle 
sizes and the polymorphic behavior of the solid 
triglyceride nanoparticles. 
This concentration dependent effect could be due to the 
relatively low SDS concentration in comparison to the 
high PVA concentration. Possibly, the SDS 
concentration is not high enough to exhibit a major 
effect on the high number of PVA molecules, which are 
located at the particle surface, or is preferably associated 
with free PVA molecules, which are assumed to be 
present in the aqueous phase. 
There were no clear indications that SDS acts as main 
stabilizer by adding it after homogenization. A 
particularly prominent indication that PVA was still the 
main stabilizer is the less ordered structure of the 
particles after crystallization, which was not observed 
for SDS-stabilized triglyceride particles [Bunjes et al., 
2002]. 
CONCLUSIONS 
This study indicated that PVA-stabilized solid 
tripalmitin nanoparticles can undergo polymorphic 
transitions into more stable modifications more easily 
after the addition of SDS. This knowledge is important 
for the estimation of the stability of the product as 
potential drug delivery system. Furthermore, the 
addition of SDS might contribute to a better 
understanding of how PVA physically stabilizes the 
triglyceride nanoparticles and induces such a high 
stability of the metastable α-polymorph.    
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ABSTRACT 
Antibiotic resistance is undermining public health; it is imperative that new classes of antibiotics are discovered and 
developed by companies and academic institutions alike. Previous research by this group used the excellent adaptability 
of N-heterocyclic carbene (NHC)-silver compounds, which allowed for the discovery of the lead compound 1,3-dibenzyl-
4,5-diphenylimidazol-2-ylidene silver(I) acetate (SBC3) [1]. SBC3 breaks the methicillin-resistance in Staphylococcus 
aureus (MRSA) [2] and has proven effective in in vivo tests using Galleria mellonella [3]. More recently, encouraging 
parts of the antibiotic mechanism of SBC3 were discovered, which underlines the ability of SBC3 to break antibiotic 
resistance patterns [4]. And SBC3 was tested successfully against biofilms in vitro and against MRSA in-infected mice 
in vivo [5]. In addition, a telescoped continuous flow route was developed which surpassed the previous batch approach. 
This provided for a scalable means to afford the targets in higher yield. 
STRUCTURE OF THE ANTIBIOTIC DRUG CANDIDATE SBC3 
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ABSTRACT 
Secondary nucleation is widely present in crystallisation processes and it is often relied upon to attain desirable critical 
quality attributes of crystalline products, such as polymorphic form and crystal size distribution. This is particularly the 
case in continuous crystallisation, where a good control of secondary nucleation can be crucial in order to achieve and 
maintain steady state operation.  
This work utilises rapid, small-scale experiments in agitated vials with in-situ imaging for crystal counting and sizing 
(using the Crystalline platform), to quantify nucleation and crystal growth kinetics of α-glycine across a range of 
supersaturations in aqueous solutions under isothermal conditions. Both seeded and unseeded crystallisation experiments 
were conducted. 
It was found that secondary nucleation and crystal growth rates determined from the same vials show a close correlation 
across the whole range of supersaturations investigated, which suggest a close relationship between the mechanisms of 
shear induced secondary nucleation and crystal growth in this system. 
Keywords: Crystallisation, Nucleation, Crystal Growth 
INTRODUCTION 
Crystallisation from solution is a purification process 
used throughout the pharmaceutical and chemical 
industries to achieve desired crystalline particulate 
product properties, such as solid form, particle size, 
shape and purity. Control over these particulate 
properties facilitates downstream processing and 
resulting product performance. To achieve control of 
such a crystallisation process, an understanding of 
nucleation and growth, the two fundamental stages of 
crystal formation, is required.  
In order to avoid problems associated with the intrinsic 
stochasticity of primary nucleation, secondary 
nucleation, the generation of new crystal nuclei from 
already-existing crystals, is often employed in industrial 
crystallisation. Secondary nucleation is often initiated at 
relatively low supersaturations to provide a controlled, 
steady supply of new crystals, accompanied by 
relatively slow crystal growth to achieve good 
purification and consistent process performance. This 
study aims to improve fundamental understanding of the 
relationships between crystal growth, nucleation and 
supersaturation in the metastable zone for crystallisation 
of -glycine from aqueous solutions. 
RESULTS AND DISCUSSION 
Crystal growth rates for -glycine estimated from in-
situ imaging were in good agreement with values 
reported in literature from single crystal growth 
experiments. Plotting growth rates on a linear scale 
appears to indicate the presence of a ‘dead zone’ below 
a certain supersaturation, where growth does not seem 
to take place. However, if data is plotted on a log-log 
scale, they show a clear power law dependence on 
supersaturation, as may be expected from crystal growth 
theories. Therefore, there does not appear to be any dead 
zone for crystal growth of -glycine. 
Secondary nucleation rates [B] for both seeded and 
unseeded experiments were also estimated from in-situ 
imaging. The seed crystals were prepared and added to 
vials following a previously outlined workflow1. When 
the secondary nucleation rates were shown on a linear 
scale, data seem to indicate a secondary nucleation 
13
https://doi.org/10.24355/dbbs.084-202110251021-0
threshold around S=1.1. Again, when data is shown on 
a log-log scale, they are consistent with a power law 
dependence on supersaturation. Although it cannot be 
ruled out that secondary nucleation completely ceases at 
some lower supersaturations, it can become too slow to 
measure with a given experimental technique at some 
point, and it can also become insignificant in a practical 
industrial crystallisation context. Furthermore, 
secondary nucleation rates in seeded and unseeded 
experiments were very similar (Figure 1), which is 
consistent with the concept of the ‘single nucleus 
mechanism’2: in other words even in unseeded 
conditions, crystallisation proceeds through the 
formation of a single crystal seed from solution by 
primary nucleation, with further nuclei then appearing 
through secondary nucleation from this original seed 
crystal.  
Figure 1. Comparison of secondary nucleation rates in 
seeded (red circles) and unseeded (blue circles) 
conditions plotted vs σ = S-1. 
The primary nucleation rates were then estimated from 
induction time probability distributions3 and plotted, 
along with secondary nucleation against the 
corresponding growth rates (Figure 2). The primary 
nucleation rate is much lower than secondary nucleation 
at all supersaturations suggesting that a high 
supersaturation is required to induce nucleation. 
Therefore, in a continuous crystallisation process, 
secondary nucleation is required to ensure that there is a 
constant supply of new crystals to achieve steady state 
operation.  
Crystal growth and secondary nucleation are often 
studied and presented as two conceptually separate 
processes or mechanisms. Our approach allows us to 
compare the growth rate and the corresponding 
secondary nucleation rate from the same experimental 
vials, based on the same imaging-based measurement 
and image analysis. We see that there is a close 
relationship between growth and secondary nucleation 
kinetics across a wide range of supersaturations. This 
suggests a possible mechanistic relationship between the 
two phenomena, where the secondary nucleation 
induced by fluid shear is related to growth of the crystal 
boundary layer in contact with the supersaturated 
solution, where loosely bound crystalline domains are 
swept from the boundary layer and serve as crystal 
nuclei. This effect would be clearly distinct from 
mechanical breakage or attrition of seed crystals, as 
there is no reason why such a mechanical process would 
be related to the crystal growth rate and indeed solution 
supersaturation.  
Figure 2. Primary (blue diamonds) and secondary (red 
circles) nucleation rates plotted vs corresponding 
growth rate. Secondary nucleation rate is many orders of 
magnitude faster than primary nucleation at all 
supersaturations.    
CONCLUSIONS 
Using a rapid small scale experimental technique 
utilising image analysis to quantify nucleation and 
growth kinetics, the metastable zone, primary and 
secondary nucleation kinetics and growth rates of -
glycine has been investigated. Results show that there is 
neither crystal growth dead zone nor secondary 
nucleation threshold present in this system. It is also 
shown that there is a close relationship between the 
secondary nucleation and the crystal growth rate across 
all supersaturations investigated. This work will provide 
better understanding of crystal nucleation and growth 
mechanisms while using rapid, small scale experiments 
and data analysis illustrated here should enable more 
facile crystallisation process development.  
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ABSTRACT 
Without any doubt the young technology of additive manufacturing, including 2D and 3D printing, has been 
changing the world. A wide spectrum of objects in medical and pharmaceutical field can already be successfully 
printed. This ranges from a detailed figure in the micrometer regime to a full size residential house unit made from 
concrete [Sakin et al., 2017; Doherty et al., 2020]. In the pharmaceutical sector, additive manufacturing offers the 
option of medication customization [Pravin et al., 2018]. Integrating this new technology has several advantages 
over the current, well-established but outdated “one-size-fits-all” approach. Besides avoiding medication errors, 
printing tailored oral dosage forms is financially attractive for small scale on-demand production [Awad et al., 
2018]. The development of dosage forms, production of sample batches and modification of samples can be done 
with little effort compared to generic powder-pressed pills which require heavy pharmaceutical machinery [Awad 
et al., 2018; Dachtler et al., 2020]. To further progress and to create the legal framework for the approval of 
additively manufactured drugs it requires a paradigm change of stakeholders who have the power to make 
decisions and changes [Horst et al., 2019]. 
Keywords: Healthcare Digitalization, Pharmaceutical Industry, Additive Manufacturing, 2D/3D Printing. 
BENEFITS OF PERSONALIZED 
MEDICATION 
Currently, the majority of pharmaceutical 
formulations have a predetermined dosage of one or 
more active ingredients [Rahman et al., 2018]. This 
is not tailored to the physiological constitution of the 
patient. Dosing drugs optimally depends on genetic, 
metabolic and gender-specific properties. Highly 
potent drugs in particular have a narrow therapeutic 
window, which varies from patient to patient. This 
calls for an individual treatment through 
personalized healthcare. Generic drugs do not meet 
the requirements for treating patients immaculately 
and there is a possibility of non-optimal or incorrect 
dosing [Reiner et al., 2020]. A wide variety of 
dosage forms and combinations of active 
pharmaceutical ingredients with tailored release 
kinetics need to be administered. This way, optimal 
therapy success is guaranteed and the risk of perilous 
medication errors is minimized. The problem of 
wrong medication should not be underestimated, as 
it is the third leading cause of death in the USA after 
cardiovascular diseases and cancer [Makary et al., 
2016]. 
The decentralized production of drugs avoids 
complex process steps involved in the “classic” 
production of solid dosage forms. The idea includes 
patient data being transmitted in digital form, for 
example from the attending physician, directly to the 
2D/3D printer in a pharmacy. The diagnosis is linked 
directly to individual medication. Small batches are 
produced cost-efficiently as required, which 
prevents drug bottlenecks or waste of active 
ingredients [Fasila et al., 2008]. Stocks of rare drugs 
can be preserved this way. 
Classic powder-pressed tablets are still the first 
choice for the mass market, as they can be produced 
time- and cost-efficiently in large quantities. 
However, individual therapy is not possible this way. 
Conventional solid dosage forms are complex 
systems made up of a wide variety of active 
ingredients and excipients [Qiu et al., 2016]. The 
development of a conventional formulation is 
therefore associated with a high level of effort due to 
possible cross-side effects.  
For new drug development, a large number of animal 
and clinical studies are necessary before a suitable 
carrier system, a generic combination of active 
ingredients and a suitable release profile can be 
found. This is where pharmaceutical 2D/3D printing 
has a decisive economic advantage. Dosage forms 
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would be developed, produced and modified at a 
minimum of cost and time.  
INDIVIDUALIZED CARE – A DISRUPTIVE 
SYSTEM 
In order to digitize the healthcare system as a whole, 
several separate players and stakeholders must be 
successfully linked. As part of a large multi-part 
disruptive system, the digital medication printing 
makes a decisive contribution to the personalization 
of medicine. Further important segments of the 
system as a whole include the use of artificial 
intelligence for data analysis, innovative methods for 
creating diagnoses and monitoring the success of 
therapy using smart data [Nohl-Deryk et al., 2018]. 
In a digitized healthcare system, active 
pharmaceutical ingredient systems are provided by 
supply companies for pharmacies, which 
manufacture tailored dosage forms on demand in 
small scales. While the doctor uses digitally obtained 
data to make an algorithm-based precision diagnosis 
for the patient, the data is forwarded directly to the 
formulator device in a pharmacy (see Figure 1). The 
reimbursement and big data collection for future 
optimization of diagnoses is carried out by the health 
insurance company [Baierlein, 2017]. Big data 
describes data sets that are, among other things, too 
large, complex, dynamic or loosely structured to be 
evaluated using conventional data processing 
methods and require innovative solutions therefore. 
THE FUTURE OF HEALTH CARE 
Medicine is a vivid science that lives from the 
introduction of innovations and new approaches and 
is therefore constantly developing. In the past, data 
acquisition in medicine was symptom-based and 
physicians depended their treatment on intuition. 
Today’s diagnoses are made on the basis of patterns 
which results in actions based on evidence. Future 
application of rules, algorithms and big reference 
databases not only enable actionable clinical 
decision support but also individually efficient care 
[Wilckens, 2014]. Algorithms are going to convert 
personally generated data sets to precision treatment. 
Various studies indicate that integrating technology 
and digitalization have a positive impact on 
treatment success [Frias, 2017]. Wearable sensors 
and mobile gadgets already have been shown to 
increase therapeutic adherence in some cases. 
Nevertheless, there is still a long way to complete 
digitization of the health system [Kvedar et al., 
2014]. 
Figure 1: The future of digital healthcare as a disruptive system including multiple steps to obtain optimal 




Awad, A.; Trenfield, S.; Goyanes, A.; Gaisford, S.; 
Basit, A. (2018): Reshaping drug development using 
3D printing. In: Drug discovery today 23(8): S. 
1547-1555. 
Baierlein, J. (2017): Grad der Digitalisierung im 
Gesundheitswesen im Branchenvergleich: 
Hinderungsgründe und Chancen. In: Digitale 
Transformation von Dienstleistungen im 
Gesundheitswesen II, Springer: S. 1-11. 
Dachtler, M.; Huber G.; Pries T. (2020): 2D & 3D-
Print-Technologien in der pharmazeutischen 
Industrie. In: Digitale Transformation von 
Dienstleistungen im Gesundheitswesen VII, 
Springer: S. 53-66. 
Doherty, R.; Varkevisser, T.; Teunisse, J.; Hoecht, 
J.; Ketzetzi, S.; Ouhajji, S.; Kraft, D. (2020): 
Catalytically propelled 3D printed colloidal 
microswimmers. In: Soft Matter 16(46): S. 10463-
10469. 
Fasola, G.; Aita, M.; Marini, L.; Follador, A.; 
Tosolini, M.; Mattioni, L.; Mansutti, M.; Piga, A.; 
Brusaferro, S.; Aprile, G. (2008): Drug waste 
minimisation and cost-containment in medical 
oncology: two-year results of a feasibility study. In: 
BMC Health Services Research 8(1): S. 1-8. 
Frias, J.; Virdi, N.; Raja, P.; Kim, Y.; Savage, G.; 
Osterberg, L. (2017): Effectiveness of digital 
medicines to improve clinical outcomes in patients 
with uncontrolled hypertension and type 2 diabetes: 
prospective, open-label, cluster-randomized pilot 
clinical trial. In: Journal of medical Internet research 
19(7): S. e246. 
Horst, A.; McDonald, F.; Hutmacher, D. (2019): A 
clarion call for understanding regulatory processes 
for additive manufacturing in the health sector. In: 
Expert review of medical devices 16(5): S. 405-412. 
Kvedar, J.; Coye, M.; Everett, W. (2014): Connected 
health: a review of technologies and strategies to 
improve patient care with telemedicine and 
telehealth. In: Health affairs 33(2): S. 194-199. 
Makary, M.; Daniel, M. (2016): Medical error - the 
third leading cause of death in the US. In: BMJ, The 
British Medical Journal 353. 
Nohl-Deryk, P.; Brinkmann, J.; Gerlach, F.; 
Schreyögg, J.; Achelrod, J. (2018): Hürden bei der 
Digitalisierung der Medizin in Deutschland - eine 
Expertenbefragung. In: Das Gesundheitswesen 
80(11): S. 939-945. 
Pravin, S.; Sudhir, A. (2018): Integration of 3D 
printing with dosage forms: A new perspective for 
modern healthcare. In: Biomedicine & Pharma-
cotherapy 107: S. 146-154. 
Qiu, Y.; Chen, Y; Zhang, G.; Yu, L.; Mantri, R. 
(2016): Developing solid oral dosage forms: 
pharmaceutical theory and practice. In: Academic 
press. 
Rahman, Z.; Ali, S.; Ozkan, T.; Charoo, N.; Reddy, 
I.; Khan, M. (2018): Additive manufacturing with 
3D printing: Progress from bench to bedside. In: The 
AAPS journal 20(6): S. 1-14. 
Reiner, G.; Pierce, S.; Flynn, J. (2020): Wrong drug 
and wrong dose dispensing errors identified in 
pharmacist professional liability claims. In: Journal 
of the American Pharmacists Association 60(5): S. 
e50-e56. 
Sakin, M.; Kiroglu, Y. (2017): 3D Printing of 
Buildings: Construction of the Sustainable Houses of 
the Future by BIM. In: Energy Procedia 134: S. 702-
711. 
Wilckens, T. (2014): Pattern diagnostics and 
precision medicine. In: Precision Medicine World 
Economic Forum 2013. 
18
https://doi.org/10.24355/dbbs.084-202110251021-0
CORONAVIRUS VACCINES – A BLUEPRINT FOR OTHER VACCINE DEVELOPMENTS? 
Julia Bialek-Waldmann1, Leander Grode1, 
1 Vakzine Projekt Management GmbH; Mellendorfer Strasse 9; 30625 Hannover; Germany; 
grode@vakzine-manager.de 
ABSTRACT 
In December 2019, a series of pneumonia of unknown cause emerged in Wuhan, China, which developed into a global 
pandemic with more than 200 million cases and 4 million deaths worldwide as of August 2021. The enveloped RNA 
betacoronavirus which was found to cause the pandemic was named severe acute respiratory syndrome coronavirus-2 
(SARS-CoV-2). Academia and industry started with non-clinical and clinical development of several SARS-CoV-2 
vaccine candidates immediately and results were achieved enormously fast. As an example, BioNTech and Pfizer got 
their joint SARS-CoV-2 vaccine approved less than eight months after trials started, while under normal circumstances 
vaccine development takes up to 10 – 15 years. In the case of the SARS-CoV-2 vaccine the extremely fast turnaround 
time from start of clinical trials to approval of the first vaccine candidates was driven by the urgent medical need and 
made possible by the mobilisation of enormous financial resources from the private and public sectors, as well as 
manpower and effort and the willingness of regulators to speed up timelines and approval processes. 
Looking at the extremely fast and successful development of several SARS-CoV-2 vaccine candidates, it is difficult to 
understand from a layman’s perspective why for others diseases like Human Immunodeficiency Virus/ Acquired 
Immunodeficiency Syndrome (HIV/AIDS) and tuberculosis (TB), which are among the top ten causes of death 
worldwide, development of effective vaccines takes so long. More than 30 years after HIV has been discovered, there is 
still no vaccine available for prevention of HIV infection. Development of several vaccine candidates has failed in clinical 
trials. The difficulties stem in large part from HIV’s unusual characteristics of replicating and mutating rapidly and high 
sequence diversity, its ability of immune system evasion and the creation of a persistent viral reservoir within the host. 
Development of the novel TB vaccine candidate VPM1002, which is designed to be a safe and effective vaccine for 
prevention of TB infection and TB recurrence, is an example of classical vaccine development. VPM1002 was invented 
in Germany, went through successful non-clinical development and is currently being tested in phase III clinical trial.  
The achievements during the last year fast development of SARS-CoV-2 vaccines during the last year have proven that 
in case of a pandemic situation and an urgent medical need, fast vaccine development is possible. The achievements were 
reached with high financial commitment and regulators have shown willingness and engagement to accelerate timelines 
for review and approval processes. It would be desirable if further vaccine developments could benefit from these efforts. 
Keywords: SARS-CoV-2, COVID-19, vaccine development 
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ABSTRACT 
Poorly separable liquid/liquid mixtures often pose a major challenge in pharmaceutical extraction. In particular, 
compounds containing a low difference of density are difficult to separate using mixer-settler setups. The Zaiput device 
can prove an advantage over present liquid/liquid extractors. The research work involves characterizing the Zaiput 
apparatus for liquid/liquid extraction of pharmaceutical compounds with the model solvent system toluene-water. The 
extraction efficiency was investigated for a solvent mixture containing toluene-acetone-water residence times. To evaluate 
the separation success, the outlet’s concentrations are measured via IR spectroscopy. 
Keywords: multi-stage liquid/liquid extraction, countercurrent liquid/liquid extraction, continuous extraction, membrane 
separation 
INTRODUCTION 
Liquid/liquid extraction (LLE) represents an important 
processing step in the pharmaceutical industry and 
becomes more popular among the separation techniques. 
Compared to distillative separation, LLE provides 
reduced energy consumption and additionally, there is 
the opportunity to process thermosensitive compounds 
due to the low operating temperature. In practice, multi-
stage processing is often carried out to achieve efficient 
separation and increase the recovery of a product. This 
approach is required when a small partition coefficient 
impedes the separation. 
The Zaiput (Figure 1) represents a new device in which 
multi-stage countercurrent liquid-liquid extraction 
(MCCE) can be realized continuously even on a 
laboratory scale. Improved extraction rates result from 
higher mass transfer coefficients at the micro and milli 
scales. The high mass transfer rates in the slug flow led 
to equilibrium at each stage prior to the separation unit. 
However, the separation of the phases is challenging 
since the surface forces dominate over the traditionally 
used gravity force. Membrane separation is based on the 
utilization of surface forces and suitable for realizing 
phase separation. This type of separation is used in the 
zaiput. 
Advantages of the Zaiput compared to conventional 
LLE apparatus include: continuous operation, 
separation of liquids with the same density or emulsions, 
the plug-and-play functionality, as well as the easy and 
direct possibility to scale-up due to a modular design. 
Figure 1: Zaiput multi-stage extraction platform 
[Weeranoppanant, 2020] 
MCCE can be divided into two types based on the 
arrangement of the contacting units: differential and 
discrete arrangement (Figure 2). Differential contacting 
includes multiple stages operating continuously in a 
single device with no separator between the stages. On 
the contrary, discrete MCCE requires phase separation 
prior to pumping to subsequent stages. As in the Zaiput 
extraction and separation operate independently, this 
setup is scalable to a large number of stages. 
LLE in industrial applications is usually arranged by 
countercurrent flow design (CC-LLE), which offers the 
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lowest consumption of extractant. With this approach, 
the aqueous raffinate is supplied from one stage to an 
earlier stage as feed, while the organic phase is conveyed 
in the reverse flow direction. Therefore, the overall 
system can achieve high recovery even if the recovery 
of the product in each stage is low. In multi-stage 
extraction, selectivity and process yield are accordingly 
decoupled, since yield depends on the number of 
extraction stages used. 
Figure 2: Two categories of MCCE’s contacting unit 
arrangement: (A) differential and (B) discrete 
[Weeranoppanant, 2017]. 
Figure 3 displays the experimental set-up. Multi-channel 
peristaltic pumps convey the liquids from one stage to 
the next. Mass transfer is realized by droplet formation 
in capillaries by segmented flow mixing. In order to 
achieve equilibrium after each stage, a phase separation 
via membrane follows subsequently. A membrane acts 
as a barrier for the two immiscible phases. Preferably, 
the membrane is wetted by one of the phases whereas 
the other remains non-wetting. Moreover, each 
separator incorporates a self-tuning pressure regulating 
element which allows fluctuations caused by inaccurate 
pumping still allow robust operation (Figure 4). In case 
of a hydrophobic membrane, the organic (wetting phase; 
green) flows through the membrane, while the aqueous 
(non-wetting phase; blue) retains it.  
Equilibrium stage is obtained when the mass transfer in 
the mixing tube is sufficiently long and the separator 
operates effectively. 
Figure 4: Schematic and photographic illustration of the 
membrane-based separator with self-tuning element 
(heavy curved line) providing a constant pressure 
difference across the membrane (vertical lines). The 
aqueous and organic liquids are shown in green and blue 
[Adamo, 2013; Weeranoppanant, 2017]. 
CHARACTIZATION OF THE DEVICE 
In this study, the applicability of the Zaiput device for 
the liquid/liquid extraction of pharmaceutically relevant 
compounds is investigated. In the first step, a model 
compound system (toluene-water) without a transition 
component is considered and investigated with regard to 
the separation performance of the membrane.  
Figure 3: Flow diagram of countercurrent extraction process; aqueous phase in blue; organic phase in red 
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For this purpose, the residence time was varied over the 
volumetric flow rates of the organic and aqueous feed 
streams at a constant number of stages N = 2. The 
experimental matrix is shown in the Table 1. 
Table 1: Variation of the volumetric flow rates of the 
experiments.  






In the preliminary tests without transition component, 
no influence could be detected when varying the volume 
flow. In all experiments, perfect separation occured so 
that retentate and permeate can already be obtained pure 
after the first residence time.  
EXTRACTION EFFICIENCY 
The obtained findings are applied to a classical ternary 
system to test the extraction efficiency. Water as the 
extraction solvent was used to extract acetone from 
toluene feed solvent. A high percentage of acetone was 
added to evaluate the system's ability to manage 
variations in flow rates across different stages. In 
addition, acetone significantly reduces the interfacial 
tension making it a challenging case study. 
Analogous to the experiments without transition 
component, different residence times were set (Table 1). 
The organic phase constituted a mixture of toluene and 
acetone in a ratio of 1:1. In all experiments, a sample 
was taken after 1, 3 and 5 residence times. The duration 
of the sampling is set in each case equal to the duration 
of one residence time. Characteristic parameters for the 
extraction process, such as the minimum residence time, 
the depletion of the transition component as a function 
of the throughput, and the stage efficiency are 
determined.  
The separation performance drops significantly during 
experiments with acetone. The permeate sample contain 
more than 20% acetone, whereas it should actually 
consist only of toluene. However, there is a trend toward 
worse separation performance in the experiments with a 
volumetric flow rate of 2.5 mL/min and above. 
MEMBRANE SELECTION 
The influence of the membrane is particularly 
noticeable, as the best results were obtained after the 
membrane was replaced. During the experiment, a 
deterioration of the separation performance is already 
evident, so that the amount of acetone in the organic 
phase increases over the course of the experiment. Since 
the duplicate determination of the tests was always 
carried out exactly one after the other, a similar course 
should have been shown if the membrane had not 
deteriorated. However, this conclusion does not occur, 
leading to the assumption that the membrane loses its 
filtering effect in the presence of toluene. Furthermore, 
the poor separation performance indicates that the 
membrane is not suitable for toluene. The influence of 
the mixing ratio of acetone and toluene is to be checked 
further, since different results can be expected with a 
lower proportion of acetone. 
ANALYTICS 
Furthermore, analytics are developed to evaluate the 
extraction success by determining the percent extraction 
and efficiency. The outlet concentration of each 
component was analyzed by IR spectroscopy. For 
calibration, signals with the highest intensity are used 
which are 1222.95 cm-1 for acetone, 733.54 cm-1 for 
toluene and 3551.12 cm-1 for water. 
The three substances exhibit a miscibility gap, resulting 
in the formation of a two-phase system at certain mixing 
ratios which prevents the homogeneity of the sample. 
Thus, it is impossible to describe exactly the mixing 
ratio of the sample by means of a partial quantity of the 
sample. By adding a diluent, a homogeneous system is 
obtained but the detection capability decreases due to the 
dilution. The system also proves to be significantly more 
complex in terms of analysis. 
A further challenge constitutes the high volatility of 
acetone (306 hPa at 25°C), which leads to falsified 
sample compositions. To counteract volatilization, the 
samples must be measured immediately or stored 
refrigerated. 
Additionally, water has a high absorption coefficient 
compared to acetone and toluene. This leads to a 
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homogeneous broadening at certain intensities, since the 
linearity of the Lambert Beer law is limited by the 
Einstein coefficients and therefore, not all molecules can 
be energized. The high rate constant of autoproteolysis 
of water also proves troublesome. As a result, the natural 
linewidth is greatly widened and consequently, other 
signals are overlapped. 
DISCUSSION 
Operating limits can be caused by pressure difference 
either too large or too small (Figure 5). If the pressure 
difference across the membrane is large, the retained 
phase may break through. Possible reason for a high 
pressure difference can generate a low surface tension, 
which would require a replacement of the membrane. 
The flow rate also affects the internal pressure, so that a 
lower flow rate has to be set. Changing the solvent ratio 
could also led to better results. 
If the pressure is unsuitably, the permeate phase is 
partially retained by the membrane and exits with the 
retentate phase. A possible solution could be to lower 
the flow rate of the permeating phase or changing the 
solvent ratio. 
Figure 5: Schematic representation of the different 
modes of membrane-based separation: (a) under normal 
conditions; (b) breakthrough of the retained phase; (c) 
retention of the permeate phase [Adamo, 2013]. 
In the initial trials, only two-stage extractions were 
performed. For future work, higher numbers of stages 
will be investigated. Moreover, the statements obtained 
need to be reviewed by multiple determinations and 
transferred to other systems. 
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ABSTRACT 
Mixing is a crucial parameter for a wide range of processes in bio-/chemical engineering. In multiphase flows, the aim is 
a high and uniform mixing effect throughout the reaction volume without negative effects on the discrete phase. These 
are usually caused by the hydromechanical stress exerted by the mixing element. The present study introduces a novel 
reactor concept to overcome the use of fast rotating, locally acting mixing elements common in stirred tank reactors. 
Therefore, the reactor is designed of a flat, horizontally mounted cylinder, which enables mixing of the enclosed volume 
by its rotation around the central axis. To evaluate the mixing performance, a colorimetric method for mixing time 
determination is presented and the spatial evolution of mixing kinetics visualized. In addition, the method reveals the 
dependencies of the mixing time on the rotational speed and filling volume. 
Keywords: Rotating Disc Reactor, rotating reactor, local mixing time, spatial mixing time distribution, flow visualization 
INTRODUCTION 
The mixing process plays a key role in reactors for 
process engineering, since it affects the process 
performance substantially. Various objectives can be 
encountered in heat transfer, chemical reactions, 
homogenization, generation of dispersions and 
suspensions, etc. with its individual process 
requirements. In general, not only a rapid mixing is 
aspired, but also a uniform distribution of the mixing 
effect over the entire filling volume without the 
formation of insufficiently mixed fractions. 
For mixing tasks, one of the most frequently used 
reactors is the stirred tank reactor. Potentially adverse is 
the locality of the energy dissipation induced by the 
stirrer, which leads to a compartmentation [Fitschen, 
2021] and highly inhomogeneous flow regimes over the 
filling volume [Machado, 2013]. Heterogeneities may 
imply undesirable process behavior, as mixing affects 
for example, primary nucleation in crystallization 
processes [Liu, 2015] or yield and by-product formation 
in cell cultivation [Bylund, 1998]. Additionally, the high 
speed of the rotating stirrer blades, to increase the 
mixing performance, determines the mechanical stress 
on suspended particles. This can detrimentally affect 
processes such as crystallization by attrition 
[Lakerveld, 2014] or biotechnological applications with 
shear-sensitive microorganisms [Jüsten, 1998].  
To overcome the issues associated with the basic design 
of stirred tank reactors and to offer deep insights into the 
macroscopic mixing process, a method for local mixing 
time determination is presented and applied to the novel 
concept of the Rotating Disc Reactor (RDR). 
ROTATING DISC REACTOR 
As shown in Figure 1, the RDR essentially consists of a 
horizontally mounted, flat cylinder with partial filling. 
The cylinder exhibits an inner diameter of 225 mm and 
a width of 10 mm with a maximum filling volume of 
approx. 130 mL. The clamped hollow disc rotates 
around its central axis which realizes the mixing of the 
reaction volume. This way, the power input takes place 
via the large wetted surface and the RDR manages 
mixing without an intrusive mixing element. The 
intended benefit is twofold: the moving surface extends 
the mixing effect to the entire volume, as opposed to the 
local restriction of a stirrer. Furthermore, the absence of 
rapid rotating internals potentially reduces shear in 
multiphase flows despite high mixing performance, 
which will be shown in future work. 
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Figure 1: CAD drawing of the Rotating Disc Reactor 
The reactor is entirely made of transparent acrylic glass 
and illuminated by a homogeneous LED background 
panel of 30000 lumens to apply the method for mixing 
time determination by means of computer vision 
described below. 
MIXING TIME DETERMINATION 
Indicator system 
In order to display and examine the mixing process, a 
colorimetric method has been developed. Therefore, the 
volume is stained with two pH indicators according to 
the Dual Indicator System for Mixing Time [Melton, 
2002]. While methyl red turns from red to yellow in the 
pH interval 4.2 - 6, thymol blue turns from yellow to 
blue in 8 - 9.6. A narrow range with yellow color around 
pH 7 results, so that deviations in both directions - acidic 
and basic - can be displayed. The application of sodium 
hydroxide to a previously acidified indicator solution 
causes a color change from red to finally yellow with 
temporary overshoot into the basic range. This allows 
observation and objective evaluation by computer 
vision, while the local overshoot, indicated by blue 
color, can be accurately accounted for. High local base 
concentrations are not interpreted as mixed, as may be 
the case with a single indicator only. The color change 
is captured with a system camera at 25 Hz in a resolution 
of 3840 x 2160 and roughly 1.2 x 106 pixels in the region 
of interest. 
Analysis 
The algorithm to process the captured videos is written 
entirely in the Python distribution Anaconda and is built 
mainly on the packages NumPy and OpenCV. 
First, the spatial distortion of the camera is corrected by 
reference images of a dot pattern that ensures an 
accurate allocation of an identical volume fraction for 
each pixel. Without the correction, the distortion can 
lead to inaccuracies in the derivation of the mixing time 
caused by different volume per pixel representations, 
which cannot be properly considered in the subsequent 
calculations. For further information and the technical 
implementation, the reader is referred to the docs of 
OpenCV’s camera calibration. In the second step, the 
projection area of the filling volume is selected 
automatically by the logical combination of multiple 
thresholds within the color channels of the RGB color 
space and the hue in HSV color space. To obtain a 
reliable detection method, the so found preselected areas 
are converted into contours by canny edge detection and 
sorted according to their area. The contour with the 
largest area represents the correct projection area and is 
converted to a boolean mask for further use in masked 
NumPy arrays. Hence, all mathematical operations are 
performed only within the mask. 
To evaluate the individual videos, the first and last frame 
are loaded and converted to HSV color space. The 
hue (H) proves to be most suitable to track the color 
change, since it shows a large change in value while 
being least prone to light heterogeneities and noise. 
Afterwards, the pixel-based difference is calculated for 
normalization of each pixel value with its position in the 
matrix (i, j). Frame by frame, the first frame is subtracted 
and the output divided by the predetermined difference 
as shown in Eq. 1. Thus, the pixel values range from 0 
at the beginning and reach 1 in steady state.  
𝐻𝑛𝑜𝑟𝑚,𝑖,𝑗(𝑡) =
𝐻𝑖,𝑗(𝑡)−𝐻𝑖,𝑗(𝑡 = 0)
𝐻𝑖,𝑗(𝑡 = ∞)−𝐻𝑖,𝑗(𝑡 = 0)
    (1) 
Each pixel is then checked for its mixing state, in which 
the pixel is classified as mixed for values ≥ 0.95 and 
unmixed otherwise. Only the mixed pixels are summed 
up and divided by the total number of pixels in the mask 
to calculate the mixed fraction. By means of the 
percentage representation, the global mixing time is 
derived by the commonly used 95 % criterion and the 
corresponding time stamp assigned after which the 
mixed fraction fulfills the criterion for at least 5 
following time stamps. 
Mixing map 
Besides global mixing time, the spatial distribution of 
local mixing times offers advanced insights in the 
mixing process. To extract this information for all mixed 
pixels of a frame, the corresponding time stamp (t) is 
stored in a container with identical dimensions as mask. 
Before a new stamp is written to the container, the 
previous container value (i, j) is proofed zero for its 
initial state to avoid an overwrite of already classified 
pixels. Finally, the container holds all local mixing times 
and represents the spatial, so-called mixing map of the 
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reactor volume. Due to the movement of the mixed and 
unmixed regions caused by the macroscopic flow during 
the mixing process, a second container is implemented. 
This allows a partial overwrite, since all pixels which 
were mixed in the previous frame (t - 1) but are unmixed 
in the current frame (t) are reset. Therefore, the container 
considers local changes of the mixing state not only 
from unmixed to mixed but also the other way around 
and is called updated mixing map in this study. The 
maps can be divided by the respective global mixing 
time to achieve an improved comparison of mixing 
maps resulting from various operating parameters.  
RESULTS & DISCUSSION 
Both types of mixing maps provide different insights 
into the mixing behavior of the reactor and combined the 
most comprehensive results. The basic mixing map 
shown in Figure 2 displays the spatial evolution of the 
initial disturbance induced by the base application at 
position ri/di = 0,4 during rotation to the right side. 
Obviously, the main flow segments the volume into 
different compartments characterized by fractions of 
similar local mixing times. Centered near the surface 
appears an area with comparatively high mixing times 
which indicate low mixing performance. An explanation 
may be the dependence of the tangential velocity on the 
reactor radius that leads to a decrease of the local 
velocity of the wetted wall as the center of the disc is 
approached. Furthermore, a circulation flow is visible, 
represented by the darker blue color in the right half, 
bounding the low mixed area. This region contains the 
turnover point of the flow with a subsequent downward 
trailing vortex that passes tight over the darker colored 
area and ends in the center blue spot. Apparently, the 
vortex expands only in a limited space and forms a 
narrow dark band as well as a second region with less 
mixing beneath. Another characteristic of the mixing 
process can be seen from the top left, darkest blue parts, 
which show the first point of visible tracer distribution. 
Thus, after the right-hand application, the tracer has to 
move through the volume without significant expansion 
until the left turnover point is reached and the color 
changes.  
While the general mixing map reveals information 
about the macroscopic flow, the circulation of the 
colored tracer volume blurs this information in the 
updated mixing map. Therefore, the updated mixing 
map accounts for regions turning back to unmixed state 
and is not dominated by mixing times assigned at the 
beginning and during the mixing process. 
Consequently, it is primary suitable for the 
representation of critical regions, where the mixing 
takes the largest period of time. As shown in Figure 3, 
this region is located directly behind the starting point 
of the trailing vortex, as well as a region of lesser 
mixing on the lower right and a late disappearing color 
streak on the left. Whereby the latter is rather a 
statistical phenomenon. 
Figure 3: Updated mixing map, di = 225 mm, application 
position ri/di = 0,4, filling volume = 120 mL, speed = 25 rpm 
Figure 2: Mixing map, di = 225 mm, application position ri/di = 0,4, filling volume = 120 mL, speed = 25 rpm 
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Besides the local mixing time, the global mixing time is 
the scalar quantity of the mixing process, which is the 
typical parameter to compare different influencing 
factors and scale the mixing process. Figure 4 shows the 
dependence of the global mixing time on rotational 
speed and filling volume. In general, a high influence of 
the filling volume appears in an increase of the mixing 
time when the volume is also increased. This illustrates 
the importance of a suitably selected filling volume in 
order to achieve a required mixing performance. In 
addition, the mixing time becomes smaller at higher 
rotational speed, as expected. Building on the results, 
future work will extend the experimental matrix for 
different reactor dimensions to address the scaling of the 
mixing process. 
Figure 4: Influence of the rotational speed and filling 
volume on the global mixing time (95 % criterion) 
CONCLUSIONS 
The presented, computer vision based method for 
mixing time determination offers the opportunity to 
visualize the spatial kinetic of the advancing mixing 
process. With both mixing maps combined and the 
global mixing time, it is possible to obtain deep insights 
in the mixing behavior of a reactor: the dominating 
macroscopic flow, different mixing zones, critical 
regions of low mixing as a possible starting point for 
design optimizations and the scaling of the mixing 
process with the various influencing parameters. The 
derivation of local mixing times allows the spatial and 
temporal history of the mixing process to be taken into 
account. This can be utilized prospectively for a 
comparative assessment of different mixing setups and 
will be applied to the RDR compared to the standard 
stirred tank reactor. One approach may be the mean of 
the updated mixing map for similar global mixing times. 
The spatial distribution is thus converted in a 
comparable scalar quantity, which has smaller values for 
a premature, partial tracer distribution. Next to the 
proposed evaluation algorithm, the mixing behavior of a 
flat, horizontally mounted cylinder is presented for the 
first time, providing extensive opportunities for further 
investigations. 
NOMENCLATURE 
di [mm] inner diameter of the hollow disc
ri [mm] inner radius of the hollow disc
Hi,j [-] hue of HSV color space at pixel i, j 
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ABSTRACT 
Encapsulation of clinically relevant cells, such as multipotent stromal cells (MSCs), in three-dimensional (3D) core-shell 
alginate structures is a promising method for the treatment of various diseases as well as drug testing and development. 
By utilizing the alginate capsules, drugs and active substances can be delivered specifically to the desired place within 
the patients’ body. The aim of this work was to investigate the effect of cryopreservation on the integrity of cell-free 
coaxial alginate capsules after thawing using slow freezing to ensure their long-term storage. Alginate capsules were 
produced by electro-spraying and cryopreserved using different cryoprotective agents (CPAs), incubation time and 
thawing temperature. The results suggest that the capsules loaded with 10% (v/v) dimethyl sulfoxide (DMSO) and 0.3 M 
sucrose and using high thawing rates demonstrated a beneficial effect on the integrity of capsules, as compared to 10% 
(v/v) DMSO alone and applying low thawing rates. This study is a further development towards the application of 
cryopreservation for long-term storage and the emerging cell-based medicine. 
Keywords: electro-spraying, tissue cryopreservation, core-shell capsules, alginate hydrogels, membrane 
INTRODUCTION 
Regenerative medicine includes a wide range of 
applications, ranging from organ and tissue 
transplantation to highly sophisticated tissue engineered 
scaffolds and cell therapeutics [1]. In particular, stem 
cell-based cell therapies represent a promising and 
future-oriented method [2]. MSCs are increasingly 
required for therapeutic applications due to their 
differentiation ability. In turn, cryopreservation enables 
a safe and effective long-term storage of cells [2]. This 
can ensure the sufficient availability of cells [3]. Studies 
from the Food and Drug Administration (FDA) confirm 
that 80% of MSCs submissions use the cryopreservation 
for a long-term storage and preservation of cells [1]. 
However, freezing MSCs is associated with many 
complications. Cell encapsulation in hydrogels is a 
promising alternative to conventional cryopreservation 
in suspension. Alginate biomaterial is often used for this 
purpose due to its gel-forming, high biocompatibility 
and semi-permeable properties. 3D core-shell gel 
structures can be produced using coaxial electro-
spraying, where the cells are centrally positioned inside 
the alginate capsules. The hydrogel protects the cells 
from cryodamage and also acts as an extracellular matrix 
[4]. It also enables the maintenance of cellular metabolic 
activities. Moreover, the utilization of coaxial alginate 
capsules has been shown to lower immune responses in 
patients, circumventing side effects. A variation in 
membrane thickness and pore size of the envelope 
membrane allows a better control of diffusion. 
Consequently, the delivery of cell therapeutics is made 
controllable [5, 6]. 
For a successful cryopreservation in the alginate 
capsules, the osmotic effects during freezing and 
subsequent thawing, the thermal behavior of the 
capsules, and the effects of applied CPAs and their 
incubation time are important [7, 8]. Therefore, the 
development of a suitable freezing protocol is required. 
Gryshkov et al. [9, 10] have already produced and 
optimized the cell-free and cell-laden core-shell 
capsules. This paper serves to further develop and 
improve the integrity of cell-free coaxial alginate 
capsules (Ø 3000 μm) and is performed with a focus on 
the CPA loading time (45, 90 min), container type 
(cryovials), CPAs (DMSO, DMSO + sucrose), thawing 
temperature (37°C, 60°C) and thawing time (60 s). The 
aim of this parameter study is to obtain the maximum 
number of intact alginate capsules after cryo-
preservation. The capsules were prepared using the 
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electro-spraying method. The optimization of 
parameters is performed with reference to the cell 
encapsulation of MSCs and is used to improve the cryo-
preservation protocol of encapsulated MSCs within 
hydrogels, consisting of alginate. 
RESEARCH CONCEPT 
All chemicals used in this study were purchased from 
Carl Roth (Germany), unless stated otherwise. Low 
viscosity (molecular weight of 100–200 kDa [11], 
viscosity of 100–300 cP (2%, 25°C), from Sigma-
Aldrich) alginate sodium salt from brown algae was 
used in the current study. 
Preparation of coaxial capsules 
The production of cell-free core-shell capsules was 
conducted using the electro-spraying approach 
developed by Gryshkov et al. [5, 9]. The general process 
of electro-spraying included the pumping of the alginate 
solution and cell suspension at defined flow rates 
through a coaxial nozzle, the application of a high 
voltage between the nozzle and gelling solution and the 
transportation of the produced alginate droplets to a bath 
containing a gelling solution of 100 mM calcium 
chloride (CaCl2, Carl Roth) for cross-linking. For the 
core-shell capsules sodium alginates were dissolved in 
10 mM 4-(2-hydroxyethyl)-1-piperazi-neethanesulfonic 
acid (HEPES, pH 7.4) prepared in 0.9% sodium 
chloride. The final concentration of alginate solution 
was 2.5% (w/v). The membrane (alginate) and core 
(HEPES) solutions were pumped simultaneously at 
different flow rates through the custom developed 
coaxial nozzle. After gelling for 30 min, the alginate 
capsules were collected and washed once with a washing 
solution (20 mM CaCl2 in 10 mM HEPES containing 
0.9% NaCl (pH 7.4) and used for further analysis.  
The alginate and HEPES solutions were pumped 
through an outer (outer diameter 1.83 mm, B Braun) and 
inner (outer diameter 0.4 mm, B Braun) needle using 
two syringe pumps (KD Scientific). The coaxial nozzle 
was charged positively, whereas an electrode was 
grounded and immersed into the gelling solution. The 
distance between the tip of the outer needle and the 
surface of the gelling solution represents the spraying 
distance. The following parameters were applied to 
produce the alginate capsules with a centrally located 
core and with an outer diameter of 3000 ± 99 µm, an 
inner diameter of 1700 ± 90 µm and a membrane 
thickness of around 650 µm: a high voltage of 12 kV and 
a ratio of the flow rate of the alginate to the inner fluid 
(HEPES) of 4:20 (ml/h : ml/h). 
Figure 1: Prepared capsules before freezing (A) and the 
damaging effects of the capsules after thawing (B–D). 
Destroyed capsules (B). Damaged capsules (C). Here 
the membrane is not intact and the gel structure is 
severely damaged. Intact capsules that have an intact 
outer layer, minor membrane damage, a barely visible 
core, and a highly visible core (D). Scale bars are 
500 μm. 
Cryopreservation 
After washing, the prepared alginate capsules were 
transferred into cryovials (TPP) with 20 capsules per 
vial and placed on ice for CPA loading. Afterwards they 
were incubated for 45 and 90 min in two different 
cryoprotective solutions: 10% DMSO (DM) and 10% 
DMSO with 0.3 M sucrose (Sigma-Aldrich) (DMS). 
The cryoprotective solutions were prepared in a pure cell 
culture medium supplemented with Fetal Bovine Serum 
(FBS, Biochrom) in a final concentration of 20% (v/v). 
In this study, the capsules were frozen “in air”, which 
included removal of the excess of the CPAs after 
loading. The samples were frozen with 1 K min-1 to 
-80°C in the controlled rate freezer Planer Kryo 560-16
(Planer) and stored in liquid nitrogen in a cryogenic
(Fischer Scientific) at -140°C for at least 7 days.
Thawing was realized in a water bath pre-warmed to
37°C or 60°C with gentle shaking for 60 s. The last
thawing step included addition of pre-warmed
Dulbecco’s modified Eagle’s (DMEM, Biochrom)
(37°C or 60°C). After thawing, the capsules were
transferred into 6-well culture plates (TPP) and used for
further analysis. Analysis and imaging of the capsules
were performed using an AxioVert. A1 microscope and
ZEN Blue software (Zeiss). The data referring to the
capsule integrity was derived according to the damaging
effects to the alginate capsules as shown in Figure 1:









Each experiment was repeated three times. The results 
are represented as mean ± standard deviation (SD) and 
the values of the intact capsules were assessed for 
normality according to the applied Shapiro-Wilk test.  
Figure 2: Capsules’ integrity after thawing with an 
incubation time of 45 and 90 min in 10% DMSO (DM) 
and 10% DMSO with 0.3 M sucrose (DMS). 
Categorized as [B] destroyed, [C] damaged, and [D] 
intact. (n = 120). 
RESULTS 
In this study, core-shell capsules were produced from 
freshly prepared alginate solutions and samples were 
analyzed before and after freezing. The effect of 10% 
(v/v) DMSO (DM) for the applied incubation time of 45 
and 90 min (Figure 2) showed that the number of intact 
alginate capsules increased with an increasing thawing 
temperature and incubation time. For an incubation time 
of 90 min and a thawing temperature of 60°C, 45% of 
alginate capsules were intact. The percentage for (C) 
was 15% and for (B) 40%. The lowest capsule integrity 
was obtained with the incubation time of 45 min and the 
temperature of 37°C. The percentage of intact capsules 
was 28%. Completely destroyed were 60% and 
damaged 13%. 
Applying the second cryoprotective solution, DMS had 
different effects on the capsule integrity (Figure 2). The 
result show that the application of sucrose led to a 
decrease of destroyed and damaged capsules. 
Consequently, the samples that were thawed at 37°C and 
incubated for 45 min had a percentage of 52% of intact 
capsules. Therefore, these were classified in (D). The 
percentage of capsules assigned to (C) was 12% and for 
(B) the percentage was 37%. Increasing the temperature
to 60°C, while keeping the incubation time constant at
45 min, caused an increase in intact capsules. The
percentage of capsules allocated to (D) was 59%. 17%
of the capsules were considered damaged and 24% were
completely destroyed. The results (Figure 2) show the
effect of the incubation time of 90 min on the capsule 
integrity. Applying a thawing temperature of 60°C and 
an incubation time of 90 min accounted for 68% of intact 
capsules. The best overall results were obtained by using 
this combination of parameters. Here, 24% of the 
capsules were found completely destroyed and 8% 
damaged. 
DISCUSSION 
Alginate has been investigated and used therapeutically 
and diagnostically for many biomedical applications due 
to its biocompatibility, low toxicity and relatively low 
cost [6, 12]. The semi-permeability of the alginate 
hydrogel allows the transport of drugs, nutrients, oxygen 
as well as metabolic products through the alginate, but 
prevents the attack of high molecular weight substances 
such as antibodies on the cells transported within the 
alginate capsules. The idea behind using electro-
spraying approach is a coaxial flow of two liquids: 
alginate as an outer membrane and a cell suspension as 
a core. Moreover, the core-shell capsules size and the 
thickness of the alginate membrane can be varied [9, 
10]. Based on the results obtained, it can be seen that the 
alginate hydrogel is an important factor in successfully 
preserving the alginate capsules using the optimal 
freezing protocols. Cryopreservation of the low-
viscosity alginate capsules was successfully carried out 
with different percentages of CPAs, independent of the 
incubation time and thawing temperature. 
In the current study several damaging effects can be seen 
which occur during cryopreservation. This could be due 
to several reasons: short incubation time of CPAs, poor 
penetration of CPAs into the alginate capsules, without 
using of sucrose as well as the thawing time and 
temperature.  
Herein, we also analyzed the effect of the application of 
sucrose and high thawing temperatures. The utilization 
of a longer incubation time allowed an extended 
penetration of the CPA into the alginate capsules. Due 
to this, the protective properties increased which was 
reflected in the increase of intact capsules [10]. The 
longer incubation time caused a 6% increase in capsule 
integrity. The use of sucrose also supported the capsule 
integrity due to the fact that sucrose promoted 
dehydration and reduced the water content in the 
capsules [13]. Consequently, it prevented capsule 
bursting, and reducing the number of destroyed 
capsules. The addition of sucrose resulted in an average 
increase of 15% in integrity. Although a better result was 
obtained by the longer incubation time, it is inadvisable 
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to increase the penetration time of CPAs. In case a 
colonization of cells occurs, CPAs may be toxic to the 
cells over a longer period of time [2, 14]. 
CONCLUSIONS & OUTLOCK 
In this paper we showed the effect of cryopreservation 
on the integrity of cell-free coaxial alginate capsules. 
The study was carried out for different process 
parameters: variation of the incubation time, CPAs and 
thawing rates. The aim of this study was to analyze the 
combination of parameters that showed the maximum 
number of intact alginate capsules and was performed in 
view of establishing the freezing protocol for 
encapsulated MSCs. In this study, we observed that the 
percentage of intact capsules increased with increasing 
incubation time and thawing temperature. The addition 
of 0.3 M sucrose to 10% DMSO caused an increase in 
capsule integrity. Almost 70% of the capsules survived 
after thawing and short-term storage. For the further 
optimization of the freezing protocol, which could result 
in an increase of intact alginate capsules, would be 
interesting: increasing the sucrose content, analysis of 
different cooling rates, optimization of freezing by 
applying cryobags as well using electroporation-assisted 
delivery of sucrose and trehalose or similar into MSCs. 
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ABSTRACT 
Spherical agglomeration (SA) is a key crystal shape modification technique commonly used to improve processability 
and physical properties of active pharmaceutical ingredients (APIs), such as flowability and dissolution. SA involves the 
introduction of a bridging liquid in the form of droplets into a suspension of API crystals. A novel approach was 
successfully implemented in this study by adopting a membrane emulsification (ME) system to control the size of bridging 
liquid droplets and spherical agglomerates. The study investigated ways to achieve the critical quality attributes of the 
spherical agglomerates by varying operating conditions and design parameters, including mixing rate, bridging liquid 
injection rate and membrane pore diameter. Antisolvent crystallization of benzoic acid in ethanol (solvent) and water 
(antisolvent) in presence of toluene as a bridging liquid was used as a case study. Spherical agglomerates of benzoic acid 
with enhanced quality attributes and mean size of 300 µm were obtained using a membrane pore size of 18 µm, a bridging 
liquid flow rate of 0.025 mL/min and mixing rate in the range of 800 RPM and 1000 RPM.  
Keywords: spherical agglomeration, membrane emulsification, droplet size, benzoic acid 
INTRODUCTION 
Crystallization is widely adopted in the pharmaceutical 
industry to purify active pharmaceutical ingredients. In 
crystallization, the most important challenges are the 
control of crystal size and shape distributions, 
polymorphism, and purity. These properties 
significantly impact the critical quality attributes of the 
drug product, such as solubility and efficacy, as well as 
the downstream processability of the resulting crystals 
such as flowability and filterability (Fysikopoulos et al., 
2019). Compared to cuboid and spherical crystals, 
handling needle-like and plate-like crystals is very 
challenging due to their very poor flowability and 
filterability and tendency to break during operation. 
Several techniques have been developed to modify the 
crystal shape and aspect ratio including wet milling (Lo 
et al., 2012), shape additives (Hatcher et al., 2020; 
Fysikopoulos et al., 2019), layer crystallization (Zhou et 
al., 2013) and spherical agglomeration (SA) (Orlewski 
et al., 2018; Peña et al., 2019). 
SA is an important shape modification technique which 
may reduce the number of unit operation and processing 
steps commonly adopted in the pharmaceutical industry 
by eliminating processes such as wet granulation. SA is 
essentially achieved by adding an appropriate bridging 
liquid at a specific ratio with respect to the mass of 
crystals, high enough to wet the particles and control the 
agglomeration process. An effective way to achieve this 
objective is add the bridging liquid in the form of 
droplets. Depending on the droplet size of the injected 
bridging liquid, several mechanisms come into play 
during the formation of the spherical agglomerates such 
us adsorption and immersion. The particle size and 
critical physical properties of the spherical agglomerates 
are determined by the droplet size distribution of the 
bridging liquid, mixing conditions and the level of 
supersaturation.  However, the control of the droplet size 
distribution may be a very challenging task particularly 
at large scale.  
In this work, we propose a novel SA approach based on 
a membrane emulsification system (Holdich et al., 2010) 
to effectively control the droplet size distribution of the 
bridging liquid which in turn can help enhance the 
critical quality attributes of the spherical agglomerates. 
Membrane emulsification is a membrane-assisted 
dispersion process used to generate emulsions of one 
liquid phase in another immiscible liquid phase, 
commonly used for oil and water emulsions. It is 
demonstrated that the membrane pore size widely 
affects the size and dispersity of the droplets formed. 
Membrane emulsification systems can be found in many 
configurations. The one used in this paper employs a 
dispersion cell with a glass chamber and a nickel 
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membrane at the bottom, where the dispersed phase can 
be injected through.  
The objective of this study is to enhance the critical 
quality attributes of the spherical agglomerates of 
benzoic acid by optimizing the critical process 
parameters (i.e., operating conditions and design 
parameters) of a fed-batch membrane emulsification 
system. To achieve this objective, an experimental 
investigation was conducted to analyze the impact of the 
bridging liquid flow rate, mixing rate, and membrane 
pore size on the droplet size and consequently of the size 
distribution of the spherical agglomerates. In addition, a 
mathematical model was used to predict the mean 
droplet size, under the investigated operating conditions, 
and its impact on the measured mean size of the 
spherical agglomerates. 
RESEARCH CONCEPT 
Materials and Methods: A dispersion cell, supplied 
with a glass chamber holder and a two-blade paddle 
stirrer, which can hold a flat disc nickel membrane with 
a pore radius was used, 𝑑𝑑𝑝𝑝 = 18 𝜇𝜇𝜇𝜇 and 33 𝜇𝜇𝜇𝜇. Anti-
solvent crystallization was performed using 30 wt% 
benzoic acid (Sigma Aldrich) dissolved in 99.8% 
ethanol (Fisher Chemical) as the solvent, with deionized 
water as the antisolvent. Toluene (Fisher Chemical) was 
used as bridging liquid, to form droplets through the 
membrane, which would allow for the spherical 
agglomerates to form. A bridging liquid to API solid 
weigh ratio (BSR) of 0.7 was used. The crystals were 
observed under an optical microscope (Nikon Eclipse 
E100) and fluorescent (Nikon Eclipse TE300) off-line at 
the end of each crystallization and agglomeration 
experiment. Agglomerate size was analyzed and 
measured from optical images using ImageJ. 
The spherical agglomeration was achieved in three main 
steps as shown in Figure 1. Firstly, the crystals were 
formed using an antisolvent crystallization. A solution 
of 30 wt.% benzoic acid dissolved in ethanol was added 
to 36 mL of water present in the dispersion cell to create 
supersaturation conditions. Once crystals were formed 
and the system reached equilibrium, the bridging liquid 
was fed into the system through the membrane forming 
droplets which initiated the agglomeration process. In 
the last step, the spherical agglomerates continued to 
form and grow in absence of any new bridging liquid 
droplets. Benzoic acid crystals obtained at the end of the 
crystallization step exhibited mainly needle-like shapes. 
  Crystallization      Droplet addition       Agglomeration 
Figure 1: Spherical agglomeration steps 
RESULTS AND DISCUSSION 
Figure 2 shows the mean size of the bridging liquid 
droplets as a function of shear stress (mixing conditions) 
for 2 different membrane pore sizes predicted by a 
mathematical model which is not presented here for the 
sake of brevity. This clearly shows that the droplet size 
decreases as the shear stress increases, and smaller 
droplets can be obtained with smaller membrane pore 
sizes. Most importantly, the size of the spherical 
agglomerates obtained at different bridging liquid flow 
rates indicate that smaller spherical agglomerates were 
obtained, as the droplet size decreases then tends to 
reach a minimum value.  To gain better insights, it is 
important to analyze the size distribution of the spherical 
agglomerates of benzoic acid.  The agglomerate size 
distribution (ASD) is represented in Figure 3 at three 
different flow rates of the bridging liquid (Qinj) and at a 
mixing rate of 800 RPM. Based on these results, smaller 
mean agglomerate sizes were obtained at lower bridging 
liquid feed rates (Qinj). In addition, Figure 3 shows that 
broader size distributions were obtained at high and low 
bridging liquid feed rates (Qinj = 0.05 mL/min and Qinj = 
0.01 mL/min).  The best spherical agglomerates were 
obtained at a medium flowrate Qinj = 0.025 mL/min.  
Figure 2: Predicted droplet size at membrane pore diameter 
dp=18 and 33µm as a function of shear stress and 






















Figure 3: Agglomerate size distribution (ASD) of spherical 
agglomerates formed at varying Qinj and 800 RPM, nickel 
membrane, dp = 33µm. 
 
Figure 4: Optical microscopy of the spherical agglomerates of 
benzoic acid obtained at Qinj = 0.025 mL/min and (a) 600 
RPM, dp = 33µm (b) 800 RPM, dp = 33µm (c) 1000 RPM, dp 
= 33µm (d) 1000 RPM, dp = 18µm. 
Figure 4 shows the optical microscopy of the spherical 
agglomerates obtained at the same bridging liquid feed 
rate of 0.025 mL/min at different mixing rates with 2 
different membrane pore diameters. The first three 
images (a-c) represent the spherical agglomerates 
obtained using a membrane with dp = 33 µm at different 
mixing rates, and (d) the spherical agglomerates with a 
membrane of dp = 18 µm at 1000 RPM. These results 
show that large agglomerates with large size distribution 
are obtained at a lower mixing rate.  The best spherical 
agglomerates were obtained under a mixing rate of 800 
RPM and 1000 RPM, under the same Qinj = 0.025 
mL/min and using the same membrane pore size. 
Although the spherical agglomerates obtained under a 
high mixing rate (1000 RPM) using a small membrane 
pore size (dp = 18µm), depicted in Figure 4d, look 
similar to those obtained under the same mixing rate but 
with a larger pore size (Figure 4c), the shape distribution 
and sphericity is enhanced in the latter case. 
As no surfactant was added, it was not possible to 
stabilize and measure off-line the actual size of droplets 
formed at the membrane surface. The presence of 
surfactant would allow the formation of more stable 
small droplets which could result in smaller spherical 
agglomerates. However, the presence of surfactant may 
also prevent agglomeration. A process analytical tool 
such as particle video microscope (PVM) may be 
employed to measure the size of droplets in real time. 
However, due to the small size of the dispersion cell, the 
integration of a PVM probe was not possible. These 
limitations can be addressed in our future scale-up 
investigation. Nevertheless, a first principle 
mathematical model was used to predict the mean 
droplet size and its influence on the measured properties 
of the spherical agglomerates.  
CONCLUSIONS 
Spherical agglomerates of benzoic acid were obtained 
using a novel approach based on membrane 
emulsification system. The impact of the operating 
conditions and design properties were investigated and 
proved that the system is flexible and suitable to 
optimize the properties of the spherical agglomerates of 
benzoic acid. These advantages suggest that the process 
can be scaled-up reliably which will be the focus of our 
future work. 
The optimization approach was based on both 
experimental observations and model predictions of the 
mean size of the bridging liquid droplets. However, a 
more rigorous modeling approach may be required to 
predict the properties of the spherical agglomerates.  
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ABSTRACT 
In this study, a novel approach was developed for determining the density of compacts using ultraviolet–visible 
spectrophotometry. The assumption within this context was that a change in density affects the corresponding color 
information of the compact. From the obtained spectra of the visible range, the color information of the compact was 
calculated which turned out to be directly proportional to the density of the compact. In comparison, the obtained spectra 
were analyzed using partial least square regression. The results of this study showed that both methods could be used 
predicting the density of a compact from the corresponding visible spectrum at identical accuracy. In contrast to the partial 
least square regression, the correlation of the color information as a direct output parameter of the spectrophotometer with 
the density required no excessive data pre-processing. Subsequently, the easier and faster data processing of the color 
information over the partial least square regression, conceives using this novel approach as potential process analytical 
technology tool for implementation into a compression process e.g., tableting or roller compaction. 
Keywords: process analytical technology (PAT), color space, tablet density, spectrophotometry, partial least square 
regression (PLS) 
INTRODUCTION 
The monitoring and controlling of the tablet or ribbon 
density and its corresponding porosity or solid fraction 
as critical quality attributes (CQAs) have become a 
major area of interest in the pharmaceutical industry 
with the goal of implementing fast and reliable 
measurement methods with the potential being used in 
process analytical technology (PAT) to ensure product 
quality particularly during continuous manufacturing.  
During the last decades, various methods have been 
investigated that are based on electromagnetic radiation 
(NIR, THz etc.). The corresponding electromagnetic 
spectra are used for the analysis of the density or other 
mechanical properties, which is usually performed by 
multivariate data analysis using principal component 
analysis (PCA) and partial least square (PLS) 
regression. 
However, little has been reported about the use of visible 
(VIS) spectroscopy for the purpose of monitoring CQAs 
of pharmaceutical compacts. Therefore, the current 
study aims to investigate the influence of densification 
on the corresponding VIS spectra (380 to 780 nm), with 
the goal to evaluate the use of this effect for determining 
the density of compacts. In this context, spectral data of 
different tablets were obtained with a UV-VIS 
spectrophotometer from ColVisTec AG (Berlin, 
Germany). In the present work, it was assumed that a 
change in the density of a compact affects the 
corresponding L*, a*, b*, C*, and h° values of the 
CIELAB color space. These values were determined for 
the compacts followed by comparing the calculated C* 
values with the density values determined from the 
geometry and weight of the compact. The obtained 
regression functions were used as prediction models for 
the density, and the properties of these functions were 
compared to PLS regression results to assess the use of 
the CIELAB color space as a novel tool for predicting 
the density of compacts.  
Note: This abstract only focuses on the evaluation of the 
CIELAB color space of one of seven blends. The results 
of the PLS regression and its comparison with the results 
of the CIELAB color space is featured in [1]. 
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MATERIAL AND METHODS 
A blend consisting of 99.5% Microcelac® 100 and 
0.5% Ligamed® was produced for the production of 
tablets. Six additional blends were made. However, the 
results are not shown in this abstract. Please refer to [1] 
for more information. A FlexiTab® (Röltgen GmbH, 
Germany) was utilized to produce four tablet batches. 
Based on the geometry and the weight of the tablets, the 
respective tablet (envelope) density was calculated.  
ULTRAVIOLET-VISIBLE MEASURMENTS 
The tablets were investigated using a spectrophotometer 
“InSpectro X” (ColVisTec AG, Germany). The probe 
was attached to a 3D printed template holding the tablet 
under investigation in a defined position. Based on the 
raw spectral data, the device calculated the L*, a*, b*, 
C*, and h° values using the spectral information in the 
range of 380 to 780 nm for each measurement. 
CIELAB COLOR SPACE 
Linear regression was used to investigate whether the 
C* value systematically correlated with the density of 
the tablet. 
RESULTS 
From the raw spectral data curves, the UV-VIS 
spectrophotometer calculated the L*, a*, b*, C*, and h° 
values of the sample under investigation. No pre-
processing of the spectral data was performed. The C* 
value was calculated based on the a* and b* values and 
was used for a direct correlation with the measured 
(envelope) density of each individual tablet, according 
to the assumption that a change in density affects the 
corresponding color information of the sample. The 
results of the regression analyses are shown in Fig. 1. 
For each blend, a good linear relation between the C* 
value and the density of the tablets was observed, despite 
the overlap and shift in the raw spectra. 
Fig. 1. Linear correlation of the C* value with the tablet 
(envelope) density.  
DISCUSSION 
The present study was designed to assess the 
applicability of the use of a compacts color information 
for determining its density. The assumption within this 
context was that a change in density affects the 
corresponding C* value of the compact. The C* value is 
a direct output parameter of the UV-VIS device and 
sufficiently sensitive to a change in density for 
predicting the density of compacts. The correlation of 
the C* value with the density can be easily and quickly 
performed and no additional software tools are required. 
The spectrophotometer is directly ready to use after 
calibration using polytetrafluoroethylene (Teflon®). 
Moreover, no pre-processing of the raw spectral data 
sets is necessary and the operator can use well-known 
linear regression to correlate the color information with 
the density. Altogether, this substantially reduces the 
amount of work required to establish and to maintain a 
model for predicting the density and applying it in 
pharmaceutical processes. Additionally, no skills 
training in multivariate data analysis and no advanced 
spectroscopic knowledge is required. This is an 
advantage over other spectroscopic techniques such as 
NIR or THz. 
CONCLUSIONS 
The present study provides a novel method for 
measuring the density of pharmaceutical compacts, 
demonstrating  that the C* value can be used for this 
purpose. Please refer to [1] for the following: 
The correlation of the C* value with the density was 
compared to the correlation based on PLS regression. 
The results of this comparison showed that the 
correlation results of the C* value were just as accurate 
as the results by PLS regression. The results of this work 
support the idea that the color information of the sample 
can be easily and effectively used for measuring the 
density using VIS spectroscopy, without the use of time-
consuming and complex spectral analysis based on PCA 
and PLS regression. 
REFERENCES 
[1] T.D. Lillotte, M. Joester, B. Frindt, A. Berghaus,
R.F. Lammens, K.G. Wagner, UV–VIS spectra as
potential process analytical technology (PAT) for
measuring the density of compressed materials:
Evaluation of the CIELAB color space, International




MULTIFUNCTIONAL USE OF CASEIN AS RELEASE SYSTEM AND BLOCKING LAYER 
FOR IMPLANT COATINGS 
N. Meier1, H. Menzel1
1 TU Braunschweig; Hagenring 30; Braunschweig / Germany; (nils.meier@tu-braunschweig.de) 
ABSTRACT 
In situ tissue engineering requires to functionalize the surfaces of implants, to achieve better biocompatibility or to release 
pharmaceuticals. Often a burst release of such pharmaceuticals takes place and the surface functionality is gone rapidly. 
Casein-micelles (M-Cas) offer unique release capabilities for hydrophobic and hydrophilic substances. In this work, 
M-Cas were reconstructed and used as release system for curcumin as a model drug. Modified electrospun
polycaprolactone (PCL)-fiber mats were coated with chitosan / tripolyphosphate nanoparticles (CS/TPP-NP) and
functionalized with the reconstructed M-Cas. [1] CS/TPP-NPs and Na-caseinate (Cas) were used as blocking layer to
slow down the release of curcumin loaded micelles. The layers were investigated by surface zeta-potential (ZP). The
release of the curcumin from surfaces was possible and the blocking layers had a significant influence on the kinetics.
Keywords: casein-micelles, surface functionalization, blocking layers, controlled release, tissue engineering 
INTRODUCTION 
Drug release systems can be applied to implant surfaces, 
for example, by means of a layer-by-layer (LbL) 
coating. These systems often suffer from a burst release. 
Furthermore, the coating process may influence the 
structure and the release of the drugs. The 
interpenetration of the layers, which are subsequently 
applied to the surface, effects the release properties, 
because often a continues layer not separated ones is 
formed. In this large layer the substances are widely 
dispensed and probably released faster as if they had to 
overcome interfaces at different layers. [2, 3, 4] 
Casein is a natural release system and offers the 
possibility of transporting hydrophilic and hydrophobic 
substances. [5] It is already used in some medical 
applications, as in the encapsulation of poorly soluble 
drugs and in bone tissue engineering as scaffold. Surface 
modification with casein was also proven feasible. 
However, working with casein or casein-micelles can be 
difficult due to preparation and purification steps. [5, 6] 
Here we report on using reconstructed casein-micelles 
as release system for modified electrospun PCL-fiber 
mats and further adjustment of the release kinetics with 
additional blocking layers of Na-caseinate. 
RESEARCH CONCEPT 
Electrospun PCL-fiber mats were modified with CS-g-
PCL and further coated with alginate. [1] In order to 
functionalize this primal scaffold with casein micelles, a 
positively charge surface was prepared with a layer of 
CS/TPP-NP. [3] The reconstructed micelles or Na-
caseinate now could be coated on the scaffold and used 
in model system to release curcumin, investigate the 
release capacity and the blocking efficiency.  
Reconstruction of Casein-Micelle 
A dialysis method was used to reconstruct casein-
micelles. Na-caseinate was dissolved in dest. water 
(50 mg/mL) and dialyzed (MWCO 3.5 kDa) against a 
5 mM CaCl2-solution. The reconstructed micelles were 
collected after 16 h and characterized by dynamic light 
scattering (DLS) (nano ZetaSizer ZS) for the size and 
zeta-potential. [7] 
Encapsulation of Curcumin 
Curcumin (1 mg/mL) was dispersed in an aqueous 
micelle solution (1 mg/mL) and was shaken (200 rpm) 
for 2 h. After an additional 1 h of resting, the loaded 






Layer-by-Layer build up 
In a dipping process CS/TPP-NPs (2 mg/mL) and 
Na-caseinate / casein-micelles (0.1 mg/mL - 5 mg/mL) 
were alternately coated onto a silicon-wafer. Each layer 
was dipped for 10 min and was washed 1 min with 0.1% 
of acetic acid (only CS/TPP layers) and water. The 
coatings were dried in a N2-stream before the 
ellipsometry measurement. [3, 9] 
Layer characterization 
Surface zeta-potential measurements (SurPASS 3) of 
the casein layer on modified fiber mats were performed 
over a pH range from 9 to 2. 
Release experiments 
Micelles with encapsulated curcumin (1 mg/mL) were 
coated on modified fiber mats (8x16 mm). A second 
group was further coated with blocking layers (2 x 
(CS/TPP(1 mg/mL)-Cas(0,1 mg/mL))). The release was 
carried out over 6 h in a Na2CO3-buffer (1 mg/mL; pH 
11), which is necessary to dissolve the curcumin and 
quantified by UV/Vis-analysis. 
RESULTS 
After 16 h of dialysis reconstructed Na-caseinate 
micelles had a size as z-average of 120 nm and a 
polydisperse index (PDI) of 0,224. The zeta potential at 
pH 7.4 was -19.1 mV. Longer dialysis time tend to result 
in smaller particles. 
 
Fig. 1: Zetapotential measured as surface streaming 
potential measurements of modified PCL fiber mats, 
with different surface functionalization’s, in a pH range 
from 9 to 2. A 1 mM KCl solution was used as 
electrolyte. Alginate is used as the negatively charged 
surface which is further coated with CS/TPP (1 mg/mL) 
and Na-caseinate (0.1 mg/mL). 
The negative charge of reconstructed casein micelles 
and Na-caseinate itself makes them applicable in a layer-
by-layer build-up alternating with positively charged 
CS/TPP nanogels. Various concentrations of casein 
were applied. A partial detachment of the casein layers 
was observed, while the next CS layer was coated. With 
less concentrated casein solution (0,1 mg/mL), no 
detachment was observed and the same thickness as 
after the detachment was reached. 
The layers were further characterized by surface 
streaming potential measurements, shown in Fig. 1. The 
surface modifications manifest themselves in a change 
of the isoelectric point (IEP) as well as the general curve 
shape.  
The release data for layers prepared with reconstructed 
casein micelles and the blocking capacity of additional 
Na-caseinate layers, is shown in Fig. 2.  
 
Fig. 2: Relative release of curcumin from fiber mats 
functionalized with reconstructed casein micelles at 
37 °C in a Na2CO3 (pH 11), a) without blocking layers 
and b) with blocking layers (2 x (CS/TPP(1 mg/mL)-
Cas(0,1 mg/mL))). The additional blocking layers 
showed a change in the release kinetics for curcumin. 
DISCUSSION 
A reconstruction of casein-micelles was possible with 
the dialysis method. Time, concentration of CaCl2, type 
of dialysis tube and the temperature are all parameters 
determining the amount and velocity of the Ca2+ 
diffusion and therefore effect the micelle formation but 
all these factors can easily be set, and the reconstruction 
was well reproducible. The casein-micelles had a z-
average size of ~120 nm, which is similar to natural 
micelles (~150 nm). The negative ZP of roughly -20 mV 
makes them applicable to interact with the positively 



















































Curcumin was passively encapsulated by the micelles, 
after 2 h of shaking and 1 h resting the solution, the 
micelles had a yellow color. A rest of non-dissolved 
curcumin was still present at the bottom of the flask, 
meaning that not all of it could be encapsulated. By 
determining the undissolved curcumin, the 
encapsulation efficiency could be calculated. The 
supernatant of the curcumin loaded micelles were used 
to build up layers for the release experiments. 
In the layer-by-layer method oppositely charged 
polyelectrolytes or particles are used to build-up the 
coating. While dipping in the CS/TPP-NP suspension 
the previously deposited casein layer was partly rinsed 
off and the layer thickness decreased somewhat. Using 
less concentrated casein solutions this effect was 
negligible, actually at a concentration of 0.1 mg/mL Na-
caseinate and casein-micelles the thicknesses reached 
the same levels as without a rinse off effect. The LbL-
method results in stable films because of the charge 
compensation of the two oppositely charged 
polyelectrolytes as well as the release of small 
counterions. [4] Furthermore, a certain degree of 
interpenetration of the layers occurs. In the case of 
higher casein concentrations besides the amount which 
is necessary to compensate the charge of the chitosan 
and to release the TPP ions, additional caseinate is 
adsorbed due to hydrophobic interactions, which are 
comparatively weak. However, this part is removed 
again when the substrate is dipped in the CS/TPP-NP 
dispersion. Interestingly the same effect occurred with 
the casein-micelles but in different extent. The layers in 
general were thicker, because of the Ca2+-crosslinks 
within the micelles, but still a rinse off effect was 
observable. Similar explanations apply here. [9] 
The coatings prepared by the LbL-method were 
characterized by surface streaming potential 
measurements (Fig1). The fundamental alginate layer, 
used as substrate for further coatings on the fiber mats 
[1] showed a typical curve shape for acid surfaces, 
where the zeta-potential rises but stays negative until 
very low pH values. In contrast, the chitosan/TPP layer 
behaves atypical. If chitosan/TPP is added as top layer 
onto the alginate a different behavior is observed (s. 
Fig1). The zeta-potential is rising faster for the alginate 
layer, but still negative. Furthermore, a plateau is 
observed. Decreasing the pH decreases the negative 
zeta-potential and at as isoelectric point of 
approximately 4 the potential turns positive This value 
is somewhat lower than expected for chitosan, Zemljič 
et. al. [10] reported an IEP of around pH 8. This can be 
reasoned to be a consequence of the interpenetration of 
the alginate and chitosan layers, resulting in a mixed 
layer. Similar observations were made by Sandri et. al. 
[11] for some chitosan systems and also attributed to the 
interaction / interpenetration of the layers, resulting in 
blended layers. 
Finally, the casein (c = 0.1 mg/mL) layer was expected 
to show interpenetration and influences from the 
underlaying chitosan layer. However, for the casein 
layer the curve shape and isoelectric point (~6) fits to the 
literature IEP of the different caseins (~5-6) depending 
on the orientation and the casein on the surface. [12] 
With these results it can been assumed, that in this case 
the zeta potential is not influenced by the underlying 
chitosan and that there is no or only weak 
interpenetration. These are important findings for the 
use of the casein as blocking layers in a release system, 
because the casein builds a separated but attached layer. 
It can by hypothesized that the amphiphilic nature of the 
casein results in a layer with an inner hydrophobic 
phase, which being a barrier for the released drug. 
Releasing curcumin from coated fiber mats with 
reconstructed casein micelles (1 mg/mL) as release 
system showed the burst release typical for this kind of 
release systems. [3] This changed markedly after the 
deposition of blocking layers (2 x (CS/TPP(1 mg/mL)-
Cas(0,1 mg/mL))) on top of the micelles. The release of 
the curcumin slowed down significantly. The total 
release curcumin fluctuated between 3.2 µg and 4.6 µg, 
what strongly depends on the available surface. This 
proved that casein can be used as blocking layer and that 
reconstructed casein micelles are indeed a possible 
release system for hydrophobic substances.  
CONCLUSIONS 
In this work casein micelles were reconstructed with a 
dialysis method and were investigated for their use as 
release system for implant coatings. The direct use of 
casein-micelles is often not possible because of the 
requirement of separation and cleaning steps. The 
reconstructed micelles are more applicable. An 
encapsulation of curcumin as model drug was possible. 
Due to the negative charge of Na-caseinate and casein-
micelles they can be used for surface modifications 
using the layer-by-layer method. Na-caseinate was used 
as blocking layer alternating with chitosan- 
tripolyphosphate nanoparticles. Surface zeta potential 
measurements indicated that the lower chitosan layer is 
not strongly interpenetrating the casein layer. The 
separation of the casein and the chitosan layers could 
provide different phases, which must be penetrated by 





as a model drug from fiber mats could be slowed down 
significantly with these additional “blocking" layers, 
realizing a more sustained release. It can hypothesized 
that the inner hydrophobic sections of the casein layers 
play a major role in the release kinetics. In future studies, 
the layer interactions will be further analyzed as well as 
the importance of the hydrophobic character. 
Furthermore, the casein system will be applied for more 
relevant drug, like for examples signaling proteins.  
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ABSTRACT 
This work presents initial design and testing of a miniaturized electrical impedance tomography platform. Electrical 
impedance tomography (EIT) provides a low-cost, non-invasive, radiation-free type of imaging and can be relatively 
easily implemented on other miniaturized systems like microfluidics. Herein, we describe a miniaturized EIT on chip, 
along with its measurement setup and image reconstruction pipeline. First imaging results demonstrating a well-
functioning setup are presented and form the basis for further investigations.  
Keywords: Electrical Impedance Tomography 
INTRODUCTION 
Electrical impedance tomography (EIT) is a low-cost, 
non-invasive, and radiation-free type of medical 
imaging [1–3]. EIT relies on the estimation of the 
conductivity of an object, based on currents/voltages 
applied to its surface. A typical medical application of 
EIT is the study of respiratory patterns. In this case, 
electrodes are placed on a transverse plane around the 
patient's chest. During breathing, the volume of the 
lungs changes. This change can be measured as a change 
in conductivity, since air and lung tissue have different 
conductivities [4]. In this project, we aim to miniaturize 
EIT for future applications in the characterization of 
biological samples on other miniaturized platforms such 
as organ-on-chip. Previous work already demonstrates 
the utility of EIT for detection/monitoring of biological 
samples and provides some proof of concept [5, 6]. The 
cost of integrating and fabricating electrodes in such 
microsystems remains low compared to the extensive 
and fast imaging results that can be achieved. However, 
progress still needs to be made on the reconstruction 
side, since low resolution remains a limitation.  
Herein, we report on the development of a simplified 
EIT-on-chip platform and first imaging results using the 
implemented measurement setup. A brief introduction to 
the principles of EIT measurement and theory of image 
reconstruction is followed by a detailed description of 
the chip, its design, and the measurement setup. Finally, 
a first EIT-imaging experiment is presented and 
discussed. 
RESEARCH CONCEPT 
EIT measurement principle 
During EIT measurements, samples are placed within an 
electrode array positioned on the inner surface of an 
imaging chamber. Then 𝑁 small alternating currents 𝑖𝑖,𝑗
are injected between electrode pairs 𝑖 and 𝑗. After a short 
delay intended to allow the electric field to build up 
inside the cell culture chamber, a series of 𝑀 voltage 
measurements are made between electrode pairs (𝑈𝑖,𝑗)
for each injection. A complete measurement set of 𝑁 ×
𝑀 voltages is obtained and used for the reconstruction 
of impedance maps. Different electrode arrangements, 
injection and measurement patterns can be used. A 
commonly used ring arrangement of 16 electrodes, as 
shown in Figure 1, is usually employed in combination 
with the “adjacent” injection and measurement pattern. 
Currents and voltages are injected and measured 
between each neighboring electrode (𝑗 = 𝑖 + 1). In this 
case, the measurement set is composed of 16 injections 




Figure 1: Principle of EIT measurement in a chamber 
with 16 electrodes arranged in a ring configuration.  
Adjacent injection and measurement pattern is 
partially shown.  
 
EIT image reconstruction 
In EIT, the conductivity 𝝈 of a body can be related to the 
measured voltages 𝑼 through a non-linear function, 𝐹, 
also known as the forward model, as: 
𝑼 = 𝐹(𝝈) (1) 
In practice, this relation is linearized and reduced to a 
Jacobian matrix 𝑱 as given in Eq. (2). This matrix 
describes the sensitivity of the electrode array for the 
given injection and measurement pattern. For more 
detailed definitions, see the works in [4, 7]. 
𝑼 = 𝑱 ∙ 𝝈  (2) 
EIT image reconstruction is achieved by solving the 
inverse problem, where 𝑼 is known and 𝝈 is searched. 
Usually this is done using standard regularization 
methods such as the one-step Gauss-Newton method 
[8]. In this work, the open-source Python package pyEIT 
has been used for image reconstruction [3]. Less 
developed than the popular open-source Matlab toolbox 
EIDORS [9], pyEIT allows rapid prototyping of EIT 
systems and is easily extensible. In pyEIT, a 2D 
chamber can be modeled as a finite element model using 
a reimplemented "distmesh" generator in Python. 
Typical dynamic EIT image reconstruction techniques 
are implemented and can be easily used.  
This work focused on time-difference imaging (see also 
frequency-difference in [6]) using the dynamic Jacobian 
matrix reconstruction method implemented in the pyEIT 
package, similar to the one-step Gauss-Newton method. 
For EIT imaging, the voltage differences ∆𝑼 = 𝑼𝒕 − 𝑼𝟎 
need to be formed from the current measured voltages 
𝑼𝒕 and the initial voltages 𝑼𝟎 (reference), and used to 
calculate the normalized conductivity changes ∆𝝈 as 
follows: 
∆𝝈 = −((𝑱𝑇𝑱 + 𝜆𝑹)−1 ∙  𝑱𝑇) ∙ ∆𝑼𝒏𝒐𝒎 (3) 
where 𝜆 is the regularization hyperparameter, 
𝑹 is the regularization matrix as: 𝑹𝑖,𝑖 = [𝑱𝑇𝑱]𝑖,𝑖




  are the normalized voltage differences. 
Here 𝜆 = 0.01, and   𝑝 = 0.5 were used. 
Chip platform 
The ultimate goal of the project is to build an organ-on-
chip platform similar to the one shown in Figure 2a, 
capable of monitoring the growth or behavior of cells (or 
other biological samples) placed/cultured in the center 
of the chamber, e.g., on a membrane. For EIT 
measurements within the chamber volume, electrode 
arrays should be integrated at the bottom and top of the 
chamber. As a first step, a simpler platform was 
developed and investigated, with an electrode array 
integrated on only one side of the chamber (Figure 2b). 
The platform consists of a 10 × 20 mm microfabricated 
chip (Figure 2c) placed in a 3D-printed holder to obtain 
an imaging chamber with a diameter of 5 mm and a 
height of  2 mm.  
 
Figure 2: a. Schematic of planned organ-on-chip with 
electrode arrays on top and bottom of cell culture 
chamber, b. chip used in this work, electrode arrays 
only on one side, c. microfabricated chip used in b.  
Electrodes of sputtered gold (about 400 nm thickness) 
were fabricated on the chip made of glass and structured 
by photolithographic wet etching. Finally, the electrical 
traces were insulated using a PECVD silicon oxide 
(SiO2) layer (about 300 nm thickness). Contact pads 
were placed at the ends of the chip for fast and easy 











































pads match the spring connectors of the PCB adapter for 
the EIT measuring device (Figure 3). 
EIT measurement setup 
An EIT device from Sciospec GmbH [10] was used for 
the EIT measurements (Figure 3). The device can 
deliver injection currents from 10 mA down to 100 nA 
with a frequency range of 100 Hz – 100 kHz and 
measure the voltages of up to 32 channels 
simultaneously. Voltages are measured using lock-in 
amplifier electronics in combination with a special 
"SineFit" algorithm from Sciospec. The connection to 
the OoC is made via a high-speed coaxial cable from 
Samtec (FCF8, see also connector FCS8). 
A custom graphical user interface (GUI) was 
implemented in Python using pyQt5 to set up the device, 
capture and store the measurement voltages. The 
corresponding top view of the chamber was captured 
using a micro-camera. Thanks to multiprocessing 
implementation, this GUI allows live viewing of the 
measurement data and EIT imaging with pyEIT at a rate 
of up to 1 frame/s. 
 
Figure 3: Micro-EIT platform connected to the 
Sciospec EIT measurement device. 
RESULTS 
To validate the measurement setup, the chamber was 
filled with Danieau's solution (conductive liquid) [11]. 
After measuring the reference/initial voltage 𝑼𝟎, an 
object (Ø1 × 0.4 mm) made of an insulator (EPDM) was 
inserted into the chamber at two different positions. For 
both positions, the voltages 𝑼𝒕𝒊 were measured and an 
EIT image was calculated using the difference with 𝑼𝟎. 
Measurements were performed with an injection current 
of 10 µA at a frequency of 10 kHz and adjacent injection 
and measurement patterns. 
Figure 4 shows both experiments, the 256 measured 
voltages differences ∆𝑼, the EIT reconstructed image, 
and a top view image of the chamber for comparison. 
The reconstructed impedance map shows normalized 
conductivity difference in comparison with the chamber 
without object. Each 16 measurements correspond to 
one injection pattern. In Figure 4a, we can observe that 
the highest voltage difference happens around injection 
#14 (𝑖14,15), which coincides with the position of the 
object. The position of the object, based on the chamber-
top-view, was added to the reconstructed image as a 
circle to appreciate the reconstruction quality. 
 













In Figure 4, same conductivity changes can be observed 
for the same object in the same liquid but at a different 
positions. Also, the position of the object in the EIT 
image matches its actual position in the chamber. This 
attests to a successful EIT imaging, validating the 
developed setup. A better contrast between the object 
and the medium can be observed in Figure 4a than in 
Figure 4b. This is related to the high sensitivity of the 
ring electrode arrangement with adjacent patterning and 
an object closer to the electrodes, as shown in [3]. 
However, this also leads to more artefacts, as observed 
in Figure 4a.  
CONCLUSIONS 
In this work, a first version of a miniaturized EIT has 
been presented and first investigations show the good 
functionality of the measurement setup and image 
reconstruction implemented on Python using the pyEIT 
package. 
In the future, further investigations will be performed 
specifically for the imaging of biological samples. 
Additionally, modeling in pyEIT should be extended for 
better modeling in 2D and 3D (e.g. with planar 
electrodes). The use of machine learning should also be 
explored to improve image resolution and quality of the 
reconstruction [7]. In the future, a closed chip design 
will be considered for constant volume during long-term 
experiments. 
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ABSTRACT 
Polymerized Ionic Liquids (PILs) are hydrogels synthesized from ionic liquids. They combine the positive characteristics 
of ionic liquids and polymers which is why they have a wide range of applications, e.g. in the pharmaceutical sector. They 
are characterized by properties such as high mechanical strength, biocompatibility, and favorable swelling behavior. In 
this study, the extremely high mechanical strength of novel polymerized ionic liquids (PILs)-based hydrogels was 
confirmed by mechanical tests. The swelling behavior was studied of hydrogels based on 1-Vinyl-3-alkylimidazolium 
bromide with different crosslinkers in various solvents – aqueous and organic. 
Keywords: Hydrogel, Polymerized Ionic Liquids, Swelling Properties, Mechanical Properties 
INTRODUCTION 
Hydrogels are a unique class of polymeric materials that 
have a three-dimensional network structure which can 
absorb and retain large amounts – from few percent to 
thousands of times their dry weight – of water without 
dissolving. The insolubility as well as mechanical 
properties or swelling behavior are due to the chemical 
and/or physical crosslinker and its amount [Hussain, 
2013]. Furthermore, there are hydrogels with a number 
of useful properties such as self-healing or 
biocompatibility [Ahmed, 2015]. Due to the favorable 
properties of hydrogels, there are numerous applications 
of hydrogels in medical and pharmaceutical fields, as 
contact lenses, as materials for artificial skin or drug 
delivery systems, but they also have potential 
applications as immobilization matrices for e.g. 
enzymes and catalysts [Grollmisch, 2018] or in other 
fields.  
Most Hydrogels, which include polymerized ionic 
liquids (PILs) are formed by click-chemistry [Boehnke, 
2015]. This has the advantage of no undesirable by-
products being formed. The remaining PILs combine the 
features of ILs (e.g., ionic conductivity, thermal, and 
chemical stability, tunable solution properties) and the 
properties of polymers [Eftekhari, 2017].  
For all the applications mentioned, however, it is crucial 
to know as much as possible about the properties of 
hydrogels in order to be able to use them in the most 
targeted way. 
SYNTHESIS OF HYDROGELS 
To characterize the hydrogels, the dimensionally stable 
PILs are being obtained by radical polymerization. An 
imidazolium-based ionic liquid bearing a vinyl group is 
polymerized with a crosslinker. Different crosslinkers, 
such as N,N’-Methylenebisacrylamide  and 
Tri(ethylenglycol)divinylether, are used (Figure 1). 
There are several variations during synthesis, which 
have a decisive effect on the synthesis of the hydrogel, 
e.g. the content and type of crosslinker, water content
and the ionic liquid monomer. At the same time,
however, the properties of the hydrogel are of course
also influenced by the variation. Another significant
influence on the properties has the storage of the
hydrogels, hence all experiments were performed with
specimens, which were dried in a climatic chamber at a
constant temperature of 25 °C and a relative humidity of
60% for different durations. All hydrogels were





Figure 1: Radical polymerization of an imidazolium-
based ionic liquid bearing a vinyl group, [VRIm][Br] – 
1-Vinyl-3-alkylimidazolium bromide and cross-linker 
1a N,N’-Methylenebisacrylamide (BisA); 2a 
Tri(ethylenglycol)divinylether (TEGDVE). APS – 





The swelling behavior of any polymer is significantly 
influenced by several factors such as the structure of the 
monomers used for hydrogel production, but also by the 
type and amount of crosslinker. Depending on the 
properties of the polymer network, the swelling 
behavior also changes with changes in external 
conditions, such as different solutions and solvents. 
Table 1: Hydrogel - solvent combinations tested for 






























poly(VEImBr/BisA) x x    
poly(ViPrImBr/BisA) x x x x x 
poly(VEImBr/TEGDVE) x     
 
Swelling measurements were performed in different 
solvents (Table 1) and analyzed gravimetrically. The 
drying conditions were 25 °C and 60% relative humidity 
(rh). The swelling ratio (SR) was determined as follows, 
as is common [Carvalho, 2013]: 
 
𝑆𝑅 =  
𝑀𝑡 − 𝑀0
𝑀0
 . (1) 
 
In Figure 2, a solvent-dependent swelling and shrinking 
can be observed. In the aqueous solutions, the hydrogel 
swells significantly, with the greatest swelling observed 
in HCl. In the solvents ethanol, acetone and ethyl acetate 
the hydrogel shrinks, with swelling occurring in ethanol 
after 1440 min. 
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Figure 2: Swelling behavior of poly(ViPrImBr/BisA) 
hydrogels in different solvents at 23 °C. 
That the swelling is not only dependent on the solvent, 
but also on the hydrogels respectively, IL monomers and 
crosslinkers used are shown in Figure 3. Here, a 
significantly higher swelling ratio can be observed with 
poly(VEImBr/TEGDVE). Poly(VEImBr/BisA) and 
poly(ViPrImBr/BisA) with the same crosslinker, show 
less difference in swelling behavior. 







 poly(VEtImBr/BisA) in 0,9 % NaCl
 poly(ViPrImBr/BisA) in 0,9 % NaCl








Figure 3: Swelling behavior of 
poly(VEImBr/TEGDVE), poly(VEImBr/BisA) and 







Due to their high water content hydrogels possess 
generally a weak mechanical strength. However, the 
advantage of PILs-based hydrogels over e.g. alginate-
based hydrogels is their significantly higher mechanical 
stability [Bandomir, 2014].  



















 poly(VEImBr/TEGDVE) in air
 poly(VEImBr/BisA) in air
 poly(VEImBr/BisA) in NaCl
 poly(ViPrImBr/BisA) in NaCl
Figure 4: Elongation tests of poly(VEImBr/TEGDVE), 
poly(VEImBr/BisA) and poly(ViPrImBr/BisA) 
hydrogels with different degrees of drying at 25 °C and 
60% rh partially in 0.9% NaCl solution with a loading 
speed of 0.1%/s. 
The mechanical properties of poly(VEImBr/BisA), 
poly(ViPrImBr/BisA), poly(VEImBr/TEGDVE) were 
analyzed by means of elongation tests (Figure 4) and 
cyclic stress-strain relations (Figure 5). The influence of 
different drying times and also the influence of the 
surrounding medium (air or physiological saline 
solution) on mechanical behavior were investigated. 















 poly(VEImBr/TEGDVE) in air
 poly(VEImBr/BisA) in air
 poly(VEImBr/BisA) in NaCl
 poly(ViPrImBr/BisA) in NaCl
Figure 5: Cyclic stress-strain relation of 
poly(VEImBr/TEGDVE), poly(VEImBr/BisA) and 
poly(ViPrImBr/BisA) hydrogels with a drying time of 
1 h at 25 °C and 60% rh partially in 0.9% NaCl solution 
with a loading speed of 0.1%/s. 
The mechanical properties are affected by the IL 
monomer, composition, cross-linking density, degree of 
drying or swelling and drying method. Depending on the 
composition, they are compressible up to 98.5% without 
crack formation in the air and up to 88.9% in 
physiological saline solution. They show a reversible 
compression up to a strain increase of max. 8% for 
poly(VEImBr/TEGDVE) hydrogels. In comparison, the 
withstand stress differs significantly. 
 
CONCLUSIONS 
Stable PILs-based hydrogels were successfully 
synthesized by a radical polymerization. Two different 
ionic liquid monomers and two different crosslinkers 
were used. The swelling behavior and mechanical 
properties of the resulting hydrogels were analyzed. It 
was shown that the swelling behavior is solvent-
dependent and depends on the composition of the 
hydrogel. The hydrogels exhibit high swelling behavior 
in aqueous media, while they shrink in organic media. 
The highest swelling ratio was observed in 0,1 M HCl. 
In a direct comparison in 0.9% NaCl solution of the 
different hydrogels, poly(VEImBr/TEGDVE) shows by 
far the greatest swelling ratio. The mechanical stability 
of the tested hydrogels has been extremely high, 
whereby the stability of the hydrogels increases with the 
drying time. The poly(VEImBr/BisA) hydrogel has 
shown a compression up to 98.5% without crack 
formation after 24 h drying time in the air and up to 
88.9% in physiological saline solution and withstand a 
stress in the air up to 19.1 kPa. In comparison, 
poly(VEImBr/TEGDVE) hydrogels break slightly 
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APS Ammonium peroxydisulfate 
Bis A N,N’-Methylenebisacrylamide  
IL Ionic Liquid 
M Mass [kg] 
PILs  Polymerized Ionic Liquids 
rh relative humidity 
SR Swelling Ratio 
TEGDVE Tri(ethylenglycol)divinylether 
TEMED N,N,N’,N’-Tetramethylethane-1,2-diamine 
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ABSTRACT 
Understanding powder flow and how it affects pharmaceutical manufacturing process performance remains a significant 
challenge for industry. This work aims to improve decision making for manufacturing route selection, achieving the key 
goal of digital design within Industry 4.0 of being able to better predict properties whilst minimizing the amount of 
material required and time to inform process selection during early-stage development. A Machine Learning model 
approach is proposed to predict the flow properties of new materials from their physical properties. The model’s 
implementation will enhance manufacturing quality by taking advantage of the data generated throughout the 
manufacturing process. 
Keywords: pharmaceutical manufacturing, pharmaceutical materials, particle characterization, Machine Learning, 
digital design. 
INTRODUCTION 
Understanding powder flow and how it affects 
pharmaceutical manufacturing process performance 
remains a significant challenge for industry, adding cost 
and time to the development of robust production routes. 
It is therefore crucial improve our understanding of 
powder flow and how this relates to both tableting and 
capsule filling. Tablet formation can be addressed by 
several techniques; however, direct compression (DC) 
and wet granulation (WG) are the most widely used in 
industrial operations. DC offers lower-cost 
manufacturing due to it provides streamlined process 
with fewer steps compared with other techniques. 
However, to achieve the full potential benefits of DC for 
tablet manufacture, this places strict demands on 
material flow properties, blend uniformity, 
compactability, and lubrication, that need to be satisfied. 
On the other hand, WG improves flowability and 
compactability while preventing segregation through the 
use of binding agents and secondary process steps 
although it is not suitable for materials which are 
sensitive to heat or moisture. WG is, therefore, more 
expensive and time consuming. Due to these economic 
advantages, DC is increasingly the preferred technique 
for pharmaceutical companies for oral solid dose 
manufacture, consequently making the flow prediction 
of pharmaceutical materials of increasing importance 
(Schaller et al., 2019; Trementozzi et al., 2017). Flow 
properties are influenced by the particle size and shape, 
which are defined upstream during crystallization and/or 
milling processes. Currently suitability of raw materials 
and/or formulated blends for DC requires detailed 
characterization of the bulk properties. A key goal of 
digital design within Industry 4.0 is to be able to better 
predict properties whilst minimizing the amount of 
material required and time to inform process selection 
during early-stage development. 
Traditionally, powder flow has been measured by 
experimental methods, such as angle of repose, bulk 
density, Carr’s compressibility index, Hausner ratio, and 
FT4 powder rheometer. However, they are time and 
material consuming, which is inefficient at the 
beginning of the material development. 
There have been several publications of different 
approaches to estimate powder flow, such as the study 
of packing efficiency based on measuring particle size 
of granular intermediates using Principal Component 
Analysis (PCA) (Sandler & Wilson, 2010), a big-data 
approach using shear cell test (Megarry, Swainson, 
Roberts, & Reynolds, 2019), the study of granular Bond 
number, which correlates to the flow function 
coefficient (Ghadiri et al., 2020); or using statistical 
modelling techniques (Barjat et al., 2021), which is 





This work aims to improve decision making for 
manufacturing route selection in the early stages of the 
drug product manufacturing process development when 
time and amount and cost of available material are at a 
premium. A Machine Learning (ML) model approach is 
proposed to predict the flow properties, specifically the 
flow function coefficient (FFc) of a new material from 
its physical particle properties. The aim is that the model 
produced as an outcome can help decide whether a new 
material is suited for DC. 
Initially, unsupervised learning algorithms were used; 
however, these were not useful to classify the data. 
Consequently, supervised learning algorithms were 
selected for classification, where FFc was defined as the 
target property (dependent variable), and the 
independent variables were particle size and shape 
distribution, and bulk density. The training data was 
experimentally generated using the Powder Rheometer 
– FT4 and a dynamic image analysis (QIC/PIC).
Furthermore, a testing data set was generated to validate
the model.
RESULTS 
The data set used to build the ML model included 115 
fully characterised materials. Regarding particle size 
distribution, 42 of the materials had a D50 smaller than 
100 µm, 56 had a D50 between 100 µm and 250 µm, and 
17 had a value of D50 greater than 250 µm. Concerning 
particle shape, most of the materials’ aspect ratio falls 
between 0.6 and 0.8, which corresponds with a cubic 
shape (Yu, Liao, Bharadwaj, & Hancock, 2017). Based 
on the FFc, the 27 materials were classified into class 1 
(cohesive materials with FFc < 4), 34 were classified 
into class 2 (easy-flowing materials, 4 < FFc < 10), and 
54 materials were classified into class 3 (free-flowing 
materials, FFc > 10). The physical particle properties 
were ranked according to their correlation with the target 
variable, resulting particle size distribution (D10 and 
D50) and aspect ratio distribution (a90) the variables 
that provided more information. 
Table 1: Number of Instances per class regarding their 
flow function coefficient and powder behaviour.  
FFc Behaviour Number of 
materials 
< 4 Cohesive 27 
4 < FFc < 10 Easy flowing 34 
>10 Free flowing 54 
The supervised learning algorithms selected were 
compared between each other to analyse their 
performance; and the model was thereafter validated 
using the external data set, for which 6 of the 8 materials 
included were correctly classified. 
DISCUSSION 
A wide range of materials were included in the training 
dataset. Among the algorithms selected, Random Forest 
(RF) exhibited the best performance (0.802), which 
means that there is a probability of 80.2 % for the 
algorithm to correctly classify the powder flow class of 
a new material. The other algorithms included in this 
study exhibited a performance higher than 70 %. 
Regarding the validation set, 75 % of the materials were 
correctly classified.  
CONCLUSIONS 
The ML model’s implementation enables the prediction 
of the material flow properties from their physical 
properties, enabling rapid decision-making regarding 
manufacturing route selection, achieving a key goal of 
digital design of being able to better predict properties 
whilst minimizing the amount of material and time 
required to inform process selection during early-stage 
development. This work suggests that particle size and 
shape distribution are sufficient to enable accurate 
prediction of flow properties, and hence, the application 
of this model will enhance manufacturing quality by 
taking advantage of the data generated throughout the 
manufacturing process.  
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ABSTRACT 
   Two-photon polymerization(2PP) is a process for three-dimensional (3D) micro-and Nano structuring based on the 
locally controlled curing of liquid precursors (light-sensitive resins) by photochemical triggered polymerization. In this 
decade, will be hearing a lot about this technic being applied to pharmaceutical applications like fabricating 3D 
microchannels for nanoparticle precipitation, nano-porous membranes and scaffolds for cell culturing, biomimetic organ-
on-chip systems. This paper presents 2pp applied microsystems for continuously generating lipid nanoparticles which are 
one of the most important drug carrier system. The most important advantages of 2pp is manufacturing 3D shapes that is 
not possible with lithographic micro and nano fabrication technologies. Also, it will be shown how 2pp fabricated 
microchannel can be integrated with continuous size measurement by flowDLS for the feed-back controlled generation 
of nanoparticles. 
Keywords: Two-photon polymerization (2PP), 3D micro structure, pharmaceutical applications 
INTRODUCTION 
   Two-photon polymerization (2PP) is an emerging 
technology for the manufacturing of 2D, 2.5D and 3D 
polymer structures with feature sizes from approx. 200 
nm to several millimeters. In the laser focus, a 
sufficiently high intensity of the laser light causes local 
non-linear absorption and polymerization and thus 
curing of the coating. The use of a galvo scanner enables 
the precise control of the laser light in the resist, which 
allows a step-by-step construction of a complex three-
dimensional object. It can be used in manufacturing of 
micro-mixers with different 3D parts like nozzles for 
coaxial injection, a sequence of stretch-and-fold 
elements and inlet filters, and many 3D structures that 
cannot be realized by conventional 2.5D techniques [1]. 
As examples Fig 1 shows two different 3D flow 
focusing micro-mixers that were fabricated with 2PP 
technics. 
Fig 1. indicates 2 different 3D flow focusing micro-mixers 
fabricating with 2PP technic.
RESEARCH CONCEPT 
With the advent of micro-mixers, another opportunity 
arose for the bottom up production of lipid nanoparticles 





water-miscible solvent is mixed with an aqueous 
solution and particles of less than 100 nm and narrow 
size distributions precipitate. A further advantage of 
microfluidic low-energy processing is that high 
temperatures, high shear stresses, high pressures and 
product contamination due to mill erosion which can 
cause damage to the active ingredients are avoided [2]. 
But still, the biggest obstacle is fouling by deposition of 
lipid on the channel walls, leading to a higher 
nanoparticle polydispersitye and even channel blocking 
[3]. Recently, a coaxial lamination mixer (CLM) 
enabled by 2PP was introduced to completely eliminate 
contact of the organic phase with the channel walls 
while efficiently mixing organic and aqueous [1]. 
    A very unique application of 2PP fabricated micro-
channels is the combination of controllable microfluidic 
nanoparticle generation with dynamic light scattering 
(DLS) for particle size analysis [6]. The system 
envisaged is a feedback-regulated nanoparticle reactor is 
to be realized with which the size, size distribution and 
shape of the manufactured particles can be precisely 
adjusted and a long-term stable process ensured. This is 
the aim of a cooperation project between   Institute for 
Microtechnology (IMT) at the TU Braunschweig with 
the flowDLS developed at the Fraunhofer Institute for 
Microtechnology and Microsystems (IMM) in Mainz. 
The necessary verification of particle properties by 
measurement and counting has so far only been possible 
within a separate analytical system after preparation is 
completed. The evaluation of the nanoparticles in a 
collected sample provides only statements about a 
sample produced within a longer period of time and does 
not open any possibilities to constantly influence the 
precipitation process in the micro mixers or the 
emulsifying systems as this is only possible by in-situ 
measurement in the channels. 
     Fig. 2 shows the important parts of the flowDLS 
system including a laser, a detector for the scattered light 
and the transparent 3D micromixer for generating 
nanoparticles fabricated with 2PP technology. Laser 
light can shine through an optical aperture into the 
channel and the scattered light can give information 
about the particle size and morphologies. 
 
 
Fig 2- The FlowDLS system for online and continuous 




  2pp can open a window of new opportunities to 
pharmaceutical engineering in fields where processes in 
micro and nano devices can be used beneficially. This 
technique enables fabrication of very complicated 3D 
designs and shapes with different non-toxic and even 
biocompatible polymers. An example is given by the 
microfluidic precipitation device that can be integrated 
with flowDLS nanoparticle measurement for feedback 
controlled nanoparticle production.   
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PHYSICAL STABILITY OF AMORPHOUS SOLID DISPERSIONS: HISTORICAL EXAMPLES 
AND SHELF-LIFE EXTRAPOLATION 
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ABSTRACT 
Amorphous solid dispersions (ASDs) of a poorly water-soluble active pharmaceutical ingredient (API) in a polymer 
matrix can enhance the water solubility and improve the bioavailability of the API. Many ASD products are kinetically 
stabilized, and the inhibition of crystallization of an API within and beyond shelf life is still a matter of debate, since the 
formation of crystals may impact bioavailability. We present the first literature examples of ASD long-term stability 
studies over up to 25 years under ambient storage conditions where no API crystallization was observed. Additionally, a 
risk assessment and mitigation strategy of API crystallization in packaged ASD drug products (DP) is outlined. The risk 
of shelf-life crystallization and the respective mitigation steps are assigned for different DP development scenarios. 
Ultimately, the physical stability of ASD DPs during shelf-life storage is modeled by quantifying crystal growth kinetics 
by transmission Raman spectroscopy (TRS), modeling the impact of water sorption on the glass-transition temperature 
of the ASD, and predicting the moisture uptake by the packaged ASD DP during storage. This approach is applied to an 
ASD of an AbbVie-internal compound showing stability beyond the anticipated shelf-life.  
Keywords: Amorphous Solid Dispersions, Crystal Growth, Transmission Raman Spectroscopy, Shelf-Life, Risk-
Assessment 
INTRODUCTION 
Poor aqueous solubility and therefore scarcity of 
bioavailability of active pharmaceutical ingredients 
(APIs) is one of the main challenges in the development 
of solid oral dosage forms during the last few decades in 
the pharmaceutical industry.[1, 2] Formulating the API 
as an amorphous solid dispersion (ASD) has been 
proven to successfully enhance bioavailability of many 
APIs classified as biopharmaceutical classification 
system (BCS) class II and class IV.[3, 4] Many ASD 
formulations are thermodynamically unstable but 
kinetically stabilized due to low molecular mobility in 
the glassy ASD formulation.[5, 6] Accelerated API 
crystallization at high drug loads (DL) in kinetically 
stabilized ASDs is considered a potential risk for both, 
patients and pharmaceutical companies.[7] 
In this work the long-term physical stability of two 
kinetically stabilized ASDs is presented: a 15 %DL 
ASD of Fenofibrate was investigated after 15 years of 
storage under uncontrolled ambient conditions, and a 20 
%DL ASD of Nifedipine even after 25 years.[8, 9] 
Those observations show that even kinetically stabilized 
ASDs can be crystal free way beyond the desired 
pharmaceutical shelf-life. 
Additionally, a strategy for crystallization risk 
assessment of ASD products, based on monitoring 
crystal growth in ASDs using transmission Raman 
spectroscopy (TRS), is discussed. Our approach 
classifies the crystallization risk in the drug product 
(DP) based on accelerated open dish studies. Depending 
on the observed data, proper mitigation steps are 
advised. In case of an anticipated crystallization in the 
packaged DP over shelf-life, the actual crystal growth in 
the DP is estimated. For this step, open dish 
crystallization rates obtained at accelerated conditions 
are combined with modeling of the glass transition 
temperature Tg and water content of the packaged  DP 
during storage. 
RESEARCH CONCEPT 
One of the key factors in ASD formulations is the 
optimization of the drug load. It is essential that the drug 
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INNOVATIVE CEROSOMES AS CARRIERS FOR AN ENHANCED DERMATOSES’ 
THERAPY 
A. Vovesná1, T. Mužíková1, J. Zbytovská1
1 University of Chemistry and Technology Prague, Faculty of Chemical Technology, Department of Organic 
Technology, Technická 5, 166 28 Prague, Czech Republic 
ABSTRACT 
Dermatoses are skin diseases caused by lowered level of lipids in the intercellular lipid matrix of skin’s uppermost layer 
stratum corneum. A promising therapy is the application of liposomally formulated skin lipids (ceramides, cholesterol, 
fatty acids). These so called cerosomes proved very effective in disrupted skin barrier repair; however, they aim primarily 
on a mechanical surface restoration. For this reason an interesting idea is to combine the cerosomes and anti-inflammatory 
drugs (such as hydrocortisone) used for the treatment of pathophysiological processes in the skin. Unfortunately, 
liposomes generally show low drug encapsulation rates, hence they would not be very effective carriers. On the other 
hand, great encapsulation effectivity can be found in lipid nanocapsules (LNCs). We therefore aimed to create a combined 
system cerosomes-LNCs that would ensure the skin barrier restoration thanks to the ceramides and simultaneously 
effectively deliver hydrocortisone as a representative of anti-inflammatory drugs into lower layers of the skin. In this 
work, we characterized the formulations by dynamic light scattering and transmission electron microscopy to assess their 
size and morphology.  
Keywords: atopic dermatitis, ceramides, cerosomes, lipid nanocapsules, hydrocortisone 
INTRODUCTION 
Human skin is the most effective barrier protecting our 
bodies from xenobiotics, UV light or bacteria. It ensures 
the proper thermoregulation and limits the water loss. 
All these vital properties are possible thanks mainly to 
the uppermost layer of the skin – stratum corneum (SC) 
and its unique composition. Its main building blocks are 
the skin cells keratinocytes that are connected by a 
complex intercellular lipid matrix. This lipid matrix 
consists of ceramides (40–50%), fatty acids (15–25%), 
cholesterol (20–25%) and cholesterol sulfate (5–10 %) 
(Harding, 2004). 
Skin, as any other organ, can be affected by a disease 
that changes or limits its basic functions. The most 
common ones one can encounter nowadays are atopic 
dermatitis, or generally dermatoses, or psoriasis. These 
diseases are accompanied by loss of skin hydration, 
dryness and elevated permeation rates of xenobiotics. 
The affected sites are reddish and itchy, which can lead 
to the necessity to scratch the area and therefore to the 
probability to carry an infection into the deeper layers of 
the skin and to further spread of the disease. One of the 
common signs of the diseases compromising the skin 
barrier is the change in the SC lipid matrix composition. 
The most notable change here is a depletion of 
ceramides and long chain fatty acids (Shao et al., 2016; 
Wolf & Wolf, 2012).  
The typical treatment of skin diseases is the application 
of ointments and creams, whose task is to ensure 
sufficient skin hydration and provide a healing 
environment. The most widely used therapy is 
application of corticosteroids and calcineurin inhibitors. 
These drugs are however administered in a form of 
suspension or dispersion, which are forms that cannot 
ensure the best biological availability of topically 
applied drugs. For this reason, we focus on the 
development of an alternative therapy concerning the 
direct application of the skin lipids, namely ceramides 
that help to restore the disrupted skin barrier properties.  
Currently, we have a very effective liposomal system 
containing skin lipids with a composition imitating the 
SC lipid matrix – so called cerosomes. These cerosomes 
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are able to effectively restore chemically disrupted skin 
barrier (Vovesná, Zhigunov, Balouch, & Zbytovská, 
2021). However, their effect is directed only to the outer 
surface disease manifestations. It is therefore vital to 
enhance this system and target even the 
pathophysiological processes in the deeper skin layers. 
For this purpose, we already have an experience with 
hydrocortisone-loaded cerosomes. Nevertheless, the 
encapsulation efficiency of cerosomes was not ideal and 
the system would not be as effective as needed. 
Typically for a topical administration of drugs, we use 
another carriers – lipid nanocapsules (LNCs). These 
nanoparticles are stable for a long time with great 
capability to encapsulate wide variety of drugs, 
including HC. We also know, that LNCs help to 
concentrate HC into SC and epidermis; however, they 
do not restore the skin barrier.  
For this reason we aim to create a combined system of 
cerosomes and LNCs with encapsulated anti-
inflammatory drug (eg. hydrocortisone). We will 
characterize the morphology of prepared particles and 
ultimately test their efficacy in disrupted skin repair and 
HC administration.  
 
RESEARCH CONCEPT 
Preparation of cerosomes-LNC system 
The cerosomes are prepared by modified method of thin 
lipid film hydration. At first, all the lipids, ceramides 3 
and 6, cholesterol and stearic acid are weighed in a 
round bottom flask and dissolved in a chloroform : 
methanol mixture. Hydrocortisone (HC) or HC-butyrate 
(HC-B) is added to this mixture as well. The ratio of 
these lipids and the drug is equimolar to best simulate 
the environment in the lipid matrix and to introduce 
sufficient amount of the drug into the formulation 
(Table 1). The solvents are then evaporated on a rotary 
evaporator until a thin film is formed on the walls of the 
flask. This film is further hydrated by phosphate 
buffered saline (PBS) solution with 10 % urea addition 
(PBS+U). The flask is alternatively placed in a heater on 
95 °C and shook on a vortex until all the lipids from the 
flask walls are dissolved. Next, LNCs are prepared by 
the phase inversion temperature method (Heurtault, 
Saulnier, Pech, Proust, & Benoit, 2002). An MCT oil 
(Miglyol 812 N), nonionic (Kolliphor HS 15) and 
amphoteric (Phospholipon 90G) surfactants are weighed 
in a beaker. HC or HC-B are also added to this mixture. 
PBS with 10 % addition of urea (PBS+U) is added and 
the whole is placed on a heater (Table 1). The mixture is 
heated three times in the range from 50 to 85 °C. After 
the third heating cycle, the mixture is diluted with ice 
cold PBS+U. The cold shock induces the nanoparticle 
formation and also the encapsulation of the drug.   
Table 1: Composition of prepared nanoparticular 
systems.  
Cerosomes LNCs 
Compound wt% wt% Compound wt% 
Ceramide 3 0.18 0.17 Miglyol 30.0 
Ceramide 6 0.18 0.18 Kolliphor 20.0 
Cholesterol 0.22 0.26 Phospholipon 1.5 
Stearic acid 0.24 0.23 HC, HC-B 0.75 
HC 0.18  PBS+U 15.0 




Urea 10.0 10.0   
PBS 89.0 89.0   
 
To combine these two systems, we took two approaches. 
One is to add the LNCs to the cerosomes. A freshly 
prepared batch of LNCs was added onto the thin lipid 
cerosomal film. The film was then hydrated and 
vortexed the same way as described above. The second 
variation of the preparation is to add the cerosomes to 
the LNCs. At first, cerosomes were prepared as 
described and then they were added to the LNC 
preparation instead the sole PBS+U.  
Particle characterization 
We characterized our nanoparticulate systems by 
dynamic light scattering (DLS) in order to get the 
information about the size of present particles. We 
describe our systems by number mean values of the size 
when we show characteristics of sole cerosomes or 
LNCs. Then to describe the combined system, we use 
volume mean values of the size for the reason that it is 
crucial to see both types of the particles largely differing 
in their sizes.  
We also established the encapsulation efficiency (EE) of 
cerosomes, LNCs and cerosomes-LNCs for 
hydrocortisone and hydrocortisone-butyrate. The EE 
was determined by ultrafiltration of a sample through 
Centrisart 20 kDa MWCO filtration units and 






RESULTS AND DISCUSSION 
At first, we prepared and characterized both systems 
(cerosomes and LNCs) respectively to find the maximal 
content of the drug (HC, HC-B) and other limits for both 
formulations. Loading cerosomes with a drug like HC or 
HC-B did not pose any challenge in terms of preparation 
conditions. It was possible to hydrate the lipid films 
containing both drugs in normal hydrating time and 
temperature (6 h, 95 °C). The resulting liposomal 
formulation was of a smooth white appearance without 
any visible large particles, crystals or aggregates. The 
particles were stored in a dark place at laboratory 
temperature in order to minimize influences on the 
particle degradation. Liposomes prepared by film 
hydration method are large multilamellar vehicles with 
quite notable variations in size leading to higher values 
of polydispersity index (PDI). Our prepared cerosomes 
showed following characteristics: HC-cerosomes were 
of 651 ± 25 nm in size with PDI = 0.37 ± 0.12. HC-B-
cerosomes did not differ significantly; they contained 
particles with size of 773 ± 45 nm, PDI = 0.45 ± 0.10. 
As the particle size is concerned, drug-loaded cerosomes 
were in every case smaller than cerosomes prepared 
without an API (active pharmaceutical ingredient). To 
show the difference, we can compare CER3+CER6 type 
of cerosomes prepared in our previous work (Vovesná 
et al., 2021). There we show the cerosomes to be 1196 ± 
238 nm large with PDI of 0.15 ± 0.02. That is notably 
bigger size than HC or HC-B loaded cerosomes with the 
same composition. We assume that this fact can be 
ascribed to the molecular shape of both corticoids. The 
base structure of the sterol core of HC and HC-B is 
similar to the structure of cholesterol; therefore, HC 
could have the tendency to incorporate itself into the 
bilayered mixed structure of the cerosomes, opposed to 
more common adherence or bonding onto or into the 
liposomes. For this reason, we also chose the total 
content of HC and HC-B to be equimolar with all other 
components. Ultimately, the lipids form 1 % of the total 
formulation and HC or HC-B stand for approximately 
0.18 % of total. The cerosomes as other liposomes do 
not possess great encapsulating capacity. That is also the 
main reason for this work on a combined system. In our 
case the encapsulation efficiency (EE) for HC was 25.3 
± 1.4 % and drug load (DL) 0.3 %. For HC-B these 
values were similar: EEHCB,cersosomes = 20.6 ± 0.9 and 
DLHCB,cerosomes = 0.2 ± 0.1 %. The encapsulation values 
around 20 % are in the expected range. DL usually 
reaches values < 10 % and for liposomes, these values 
are as always low.  
The second formulation that forms the combination are 
the LNCs. The composition of the LNCs in this work 
was optimized to hold the highest amount of HC or HC-
B possible without influencing the particle stability. The 
maximal content of the corticoids in LNCs is 0.75 % of 
the total formulation for both APIs. The size of empty 
LNC particles prepared with this composition (Table 1) 
is 101 ± 3 nm with PDI = 0.06. This size is comparable 
to other LNCs with quite same composition prepared in 
our laboratory (Pytlíková, 2020) that were sized circa 
115 nm with PDI of 0.07. The introduction of an API 
into this system changed its characteristics only 
minimally. HC-LNC contained particles of 105 ± 2 nm, 
PDI = 0.08 and HC-B-LNC were sized 113 ± 1 nm, PDI 
= 0.09. These changes are very slight and can even be 
ascribed to variation in preparation and measurements. 
As was proposed, LNCs have great encapsulation ability 
for vast variety of drugs. Our system is not an exception, 
even though the selected corticoids are generally quite 
inert and insoluble. The EE for hydrocortisone was as 
high as 87.6 ± 3.1 % and DL was 1.0 ± 0.1 %. HC-B-
LNCs encapsulated the drug by 85.8 ± 1.7 % with DL of 
1.0 ± 0.1 % also. Additionally, all these characteristics 
did not change significantly during 2 weeks storage 
time, implying that HC and HC-B loaded LNCs are 
stable system capable to incorporate notable amount of 
the APIs.  
For the last part of this work, we combined the two 
described systems in order to create a complex renewing 
and healing treatment for dermatitic conditions. The first 
approach was to use the HC(B)-LNCs as the aqueous 
phase for the HC(B)-cerosomes. However, the heating 
cycles at 95 °C seemed to disrupt and break the 
constitution of the LNCs due to such high applied heat. 
The DLS measurement revealed only particles sized 
around 1 µm, which suggests the presence of liposomal 
structures, but not the smaller LNC ones. It was not 
possible to lower the hydrating temperature for the 
ceramides would not hydrate in the needed time. We 
therefore applied another method for this combination. 
LNCs were again added onto the lipid film and the 
whole flask was placed in a water bath set at 40 °C and 
the mixture was intensely mixed overnight to simulate a 
kind of high shear homogenization conditions. After this 
time, the lipid film was completely hydrated from the 
flask walls; however, there could still be seen larger 
crystals of incompletely dissolved components of the 
formulation. The second approach to the preparation 
was to use the HC(B)-cerosomes as the aqueous phase 
of the HC(B)-LNCs. Their preparation process was not 
hindered by the exchange of PBS+U for the cerosomes 
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and was completed as described in the methods section. 
The resulting formulation was homogeneous, opalesque 
without visible particles. The DLS measurement 
confirmed the presence of two sizes of particles if 
evaluated by volume mean. For HC variation the first 
and larger peak was at 98 ± 2 nm at should belong to the 
LNC part of the combination. The second peak was 
visibly smaller and positioned at 835 ± 11 nm, which 
accords with the size of cerosomes. For HC-B the result 
was really similar. It was possible to obtain a 
formulation with two distinct sizes of 116 ± 5 nm and 
956 ± 45 nm belonging to LNCs and cerosomes 
respectively. The EE and DL for this system are yet to 
be determined. Nevertheless, from the fact that the 
formulations did not contain any visible undissolved 
crystals, which it otherwise would if the HC and HC-B 
were not dissolved, we can expect the encapsulation 
rates to be at least as good as for the LNCs, but with the 




In this work we focused on a preparation of 
nanoparticulate systems for topical delivery of 
hydrocortisone and hydrocortisone-butyrate. It was 
possible to prepare lipid nanocapsules containing 
0.75 % of HC or HC-B with 85 % encapsulation 
efficiency. Next, we successfully prepared cerosomes 
mimicking the composition of stratum corneum lipid 
matrix loaded with 0.18 % of HC and HC-B. In order to 
enhance the efficiency of dermatitic conditions 
treatment, we successfully combined the two systems 
and characterized it for the presence of both 
formulations. We propose that such complex 
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load of an oral dosage form is as high as possible from a 
commercial point of view because smaller dosage forms 
and lower pill burden are typically better tolerated.[10] 
A higher drug load in turn often reduces the physical 
stability of the ASD formulation in terms of API 
crystallization.[11] From a thermodynamic perspective, 
the API is dissolved in an amorphous polymeric matrix. 
However, in many ASD formulations, the API content 
exceeds its solubility in the matrix at storage conditions: 
the ASD is thermodynamically unstable but kinetically 
stabilized due to low molecular mobility in the glassy 
ASD.[5, 6] In general, by increasing the drug load in 
kinetically stabilized ASDs, the degree of 
supersaturation of the dissolved API in the matrix and, 
therefore, the thermodynamic driving force for API 
crystallization is increased.[12] In addition, many APIs 
have a lower glass-transition temperature (Tg) than the 
polymer, leading to reduced Tg of the ASD with 
increasing drug load (Figure 1).[8, 13] Such a decrease 
of Tg increases the molecular mobility and therefore 
reduces kinetic stabilization of the ASD.[14, 15] 
  
Figure 1: Exemplary phase diagram of a polymer-
fenofibrate system.[9] The solubility temperature at 
different compositions is depicted in blue. The measured 
Tg values of different compositions are depicted in red. 
The symbols reflect measured data and the curves show 
modeling results. Different regions can be identified in 
the phase diagram: (i) thermodynamically stable melt, 
(ii) thermodynamically stable glass, (iii) kinetically 
stable glass and (iv) the undercooled or unstable melt, 
respectively. 
The extend of stabilization and the required difference 
between storage temperature T and Tg of ASDs for 
avoiding API crystallization have been a matter of 
discussion in the literature for decades. As a rule of 
thumb, it has been assumed that a kinetically stabilized 
ASD needs to be stored at least 50 °C below Tg.[16] 
Assuming such an unnecessary high safety margin will 
hinder the development of high-drug load ASDs with 
low Tg. However, setting the safety margin to low will 
cause a potential patient safety risk. As a first measure 
to determine the physical stability of kinetically 
stabilized ASDs, long term stability studies have been 
conducted. In our studies we could show that no 
crystallization of the drug active is observed in ASDs of 
Nifedipine and Fenofibrate stored only 30 °C and even 
8 °C below Tg after 15 years and 25 years of storage, 
respectively.[8, 9]  
Despite those examples of long-term stability of 
kinetically stabilized ASDs, the demand for higher drug 
load and the occurrence of API crystallization in 
developmental stability studies makes it necessary for 
pharmaceutical development teams to have a proper risk 
assessment and mitigation strategy at hand. As time is 
of the essence in pharmaceutical development, we have 
developed a lean approach for API crystallization risk 
assessment in ASDs based on fast open dish studies, 
which excludes the patient risk of API crystallization 
over shelf-life storage while properly balancing the 
business risks involved (Figure 2).[17] 
The starting point of the risk assessment is the standard 
open dish stress test at 40 °C / 75% RH. Ifcrystallization 
is detected in this study within 14 days of storage, an 
investigation of the crystallization risk is indicated. As 
in this stage of development crystallization is usually 
detected qualitatively by polarized light microscopy, the 
next step is to quantify the crystal growth and assign a 
rate constant. This investigation is performed in a Tier I 
investigation, preferably using TRS. In our experience, 
the non-destructive nature, inherent sample averaging, 
and chemometric data evaluation make this technology 
more than suited to quantify crystal growth in ASD 
samples. From our work on long term stability, we can 
assume that an ASD taking 14 days or longer to show 
complete API crystallization in an open dish experiment 
at 40 °C / 75% RH will not present a crystallization risk 
during shelf-life storage of the packaged material.[9] In 
cases where the ASD under investigation shows a 
considerable crystallization rate, the physical stability of 
alternate formulations can be compared in a Tier II 
study. A Tier III investigation is indicated if no alternate 
formulation with sufficient stability is found, or other 
reasons, like bioavailability or manufacturability, 
indicate the usage of a formulation considered not 
physically stable. In the Tier III investigation, the 
crystallization rate constant is measured for several 
storage conditions above Tg. The rate constants can be 
correlated with the ratio of Tg over T. Calculations of the 
moisture dependence of the Tg in the ASD and moisture 
content of the packaged DP can be used to  determine 






Figure 2: Workflow of the physical shelf life modelling 
risk assessment strategy for crystallization in ASD 
formulations. An investigation of the physical stability 
is indicated if API crystallization is observed in the 
standard open dish stability investigation at 40 °C / 75% 
RH within two weeks. In a Tier I investigation, the rate 
of crystallization in the ASD is determined. If 
crystallization is sufficiently fast to indicate a shelf life 
risk, the crystal growth rate in alternate formulations is 
determined in a Tier II investigation. If no sufficiently 
stable formulation can be used, a Tier III investigation 
is indicated and the crystal growth of the DP in the 
primary packaging container is approximated.  
RESULTS 
The risk assessment strategy is now routinely applied to 
AbbVies ASD development candidates. The application 
of the complete risk assessment strategy on a model 
compound will be presented in this talk. After 
crystallization of the lead formulation candidate was 
observed in an open dish study, the rate of crystallization 
was determined and compared to alternate formulations 
(Figure 3). As the lead formulation had shown complete 
API crystallization within 3 days at 40 °C / 75% RH 
open dish condition, an estimation of the physical shelf-
life was indicated. Based on predicted water content of 
the blister packaged DP and calculated impact of water 
on the products Tg, a shelf-life till crystallinity limit of 
67 months could be estimated. 
 
Figure 3: Crystal growth in five different ASD 
formulation candidates of an AbbVie internal 
compound. The crystal growth was recorded in samples 
stored at 30 °C / 75 %RH (open dish) using TRS. The 
fraction of crystallized API normalized to total API is 
shown in dependence of time. 
DISCUSSION 
Our investigations of nifedipine and fenofibrate ASD 
DPs present, up to now, the only long-term stability 
investigations of kinetically stabilized ASDs in the 
literature and proved that such DPs can be safe over the 
shelf-life, even if stored only a few degrees below Tg. 
As crystallization still might occur in accelerated 
stability studies, pharmaceutical development teams 
require a strategy to assess and mitigate crystallization 
risk. An essential step in developing the presented fast 
risk assessment approach was determining the relation 
of the API crystallization rate with the environmental 
conditions. In the literature, different attempts can be 
found from simple Arrhenius extrapolation approaches 
to linking the crystallization with relaxation time in 
glasses. Utilizing recent glass physics approaches, we 
could successfully correlate the logarithm of the 
crystallization rate with the ratio of Tg over T. 
Combining this approach with the modeling of the water 
uptake of the packaged DP and the water induced 
change in Tg, we were able to estimate crystal growth in 
packaged DP based on fast open dish studies. Applying 
the risk assessment and mitigation strategy as presented 
in Figure 2 is aiding project development teams in 
making proper decisions regarding the crystallization 
risk of the ASD DP. In cases where crystallization of the 
API over the shelf-life is anticipated, a safe shelf-life 




With the results presented in this work, crystallization 





showstopper in ASD development. Using historical 
examples, the possibility of long-term stability in 
kinetically stabilized ASDs even if stored only a few 
degrees below Tg could be shown. Utilizing recent 
results of the investigation of glass physics in ASDs and 
combining them with physical modeling tools, a risk 
assessment and mitigation framework for API 
crystallization in ASD formulation could be developed. 
The framework enables drug development teams to 
conduct rational risk-based actions in ASD 
development. It allows to successfully bring ASD 
formulations to market that were just a couple of years 
ago discontinued due to perceived stability issues. 
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IN-LINE UV-VIS SPECTROSCOPY IN SMALL SCALE EXTRUSION AS PROCESS 
ANALYTICAL TECHNOLOGY DURING EARLY STAGE DEVELOPMENT OF 
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ABSTRACT 
The poor solubility of a large number of active pharmaceutical ingredients (API) is a major challenge in pharmaceutical 
research. Therefore, the extrusion of amorphous solid dispersions (ASDs) is one promising approach to enhance the 
dissolution rate by molecularly dissolve the API in an amorphous carrier polymer. During ASD development, crucial 
parameters as the dissolution and the decomposition need to be monitored. Within this study, a small scale twin screw 
extruder was coupled with special ColVisTec UV-Vis probes that are characterized by their small dimensions. This setup 
enables a systematic formulation development and optimization based on in-line monitoring of crucial parameters using 
small amounts of material. 
Keywords: hot melt extrusion (HME), micro compounder, formulation development, process analytical technology (PAT), 
UV-Vis spectroscopy 
INTRODUCTION 
A large number of the active pharmaceutical ingredients 
(API) that are on the market and the majority of those 
currently under development have a low solubility 
[Rodriguez-Aller, 2015]. However, the dissolution 
process is crucial for the systematic absorption of the 
active ingredient in the human body. A low solubility of 
APIs therefore often leads to a low bioavailability and 
thus an insufficient efficacy.  
A common approach to improving bioavailability is to 
increase the rate of dissolution of the API by 
administering it in the amorphous state in which the 
energy to overcome the crystal lattice has already been 
applied. For the kinetic stabilization of the amorphous 
state, the active ingredient is embedded in an amorphous 
carrier polymer with high viscosity, creating an 
amorphous solid dispersion (ASD) [Vasconcelos, 2007]. 
Hot melt extrusion (HME) enables a solvent-free 
production of ASDs by mixing and dispersing processes 
inside the extruder. In order to process the highly 
viscous polymers, extrusion processes are usually 
carried out at elevated temperatures. Furthermore, the 
solubility temperature has to be reached, which states 
the minimum required temperature for a specific API 
content to be soluble in the carrier polymer. However, 
extrusion at elevated temperatures can cause mechanical 
as well as thermal decomposition, especially if polymer 
or API molecules are thermally unstable [Matić, 2020]. 
In ASD development, this interplay of completely 
dissolve the API and simultaneously avoid 
decomposition is a major challenge. Therefore, 
appropriate process conditions need to be identified 
during early stage process development. Within this 
study, the integration of an in-line UV-Vis 
spectrophotometer during small scale extrusion of ASDs 
is evaluated in order to develop a fast-working method 




Two formulations with different drug loads were 
investigated. Griseofulvin (GRI) (Fagron, Rotterdam, 
Netherlands) and Itraconazole (ITR) (Ria International 





Copovidone (PVPVA) (Plasdone S-630, Ashland Inc., 
Switzerland) was used as carrier polymer.  
Extrusion 
The extrusion was carried out using a DSM xplore micro 
compounder (Xplore Instruments BV, Sittard, 
Netherlands), a laboratory scale extruder with two 
intermeshing conical screws, a capacity of about 5 ml, 
and a die diameter of 3 mm. An air-cooled hopper was 
used in order to prevent the materials from sticking. 3 g 
of formulation were fed into the extruder, respectively. 
The screw speed was set to 50 rpm throughout the whole 
study. The residence time of the material was set by 
operating the extruder in the recirculation mode. 
Therefore, the valve between the screw tips and the die 
was turned to the recirculation channel and opened 
immediately after the desired residence time. The 
material temperature was adjusted by the barrel 
temperature and calibrated beforehand by using a Testo 
875 IR camera (Testo SE & Co. KGaA, Lenzkirch, 
Germany). 
A systematic parameter study was performed for three 
different drug weight fractions w, as listed in Table 1. 
Seven different temperatures in specific distance ΔT to 
the expected solubility temperature Ts were selected 
[Gottschalk, 2021]. For each temperature, the extrusion 
was performed with three different residence times t in 
order to investigate its influence in addition.  
Table 1: Process conditions during the extrusion of 
GRI/PVPVA and ITR/PVPVA. 
Parameter Unit Values 
w (GRI/PVPVA) [-] 0.15, 0.20, 0.25 
w (ITR/PVPVA) [-] 0.25, 0.30, 0.35 
Residence time [min] 1, 3, 10 
ΔT to Ts  [K] -10, -7, -3, 0, 3, 7, 10 
 
Optical analysis 
The presence of remaining drug crystals and coloring 
was investigated by a visual method. Therefore, the 
extrudates were placed on a black background and 
besides a yellowish coloring it was detected, whether 
they are transparent or opaque. Thereby, a transparent 
extrudate was assessed as an amorphous solid dispersion 
whereas an opaque extrudate was considered to contain 
unresolved crystals. 
UV-Vis spectroscopy 
The in-line UV-Vis spectroscopy was performed with an 
Inspectro X spectrophotometer (ColVisTec, Berlin, 
Germany) in the transmission mode. Due to the small 
dimensions of the extruder and the die channel a special 
pair of ColVisTec probes was implemented into the 
experimental setup that differ from the standard TPMP 
probes. A range of 224 to 820 nm and a sampling rate of 
1 Hz was chosen. The obtained spectra were calibrated 
by using spectra of the pure polymer as a blank 
reference.  
 
RESULTS AND DISCUSSION 
In addition to the optical analysis and transmission 
spectra (data not shown), the extrusion of ADSs is 
evaluated based on the L* and b* value of the CIELAB 
color specification system. More specifically, the 
lightness increases with an increasing L* value, 
indicating the API dissolution in the polymer. Color 
changes from blue to yellow are represented by the b* 
value. 
 
Figure 1: L* value of GRI/PVPVA/0.15 as a function 
of temperature and residence time. 
Exemplary results shown for GRI/PVPVA/0.15 in 
figure 1 clearly indicate that the L* value increases with 
increasing temperature. In addition, an increase in the 
L* value with increasing residence time can be seen for 
a certain temperature. In particular at the temperatures 
of 156 °C, 159 °C and 162 °C, the major changes of L* 
values for different residence times can be found in 
comparison to the other temperatures. This shows that 
by reaching the solubility temperature of 159 °C and in 
a small temperature range of 3 °C below and above the 
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solubility temperature, an increasing lightness occurs. 
Here, the active ingredient is increasingly dissolved in 
the carrier polymer, so that the crystalline components 
decrease and the lightness increases as a result. 
Figure 2: b* value of GRI/PVPVA as a function of 
temperature and residence time. 
Figure 2 shows the influence of the residence time and 
the temperature on the b* value for GRI/PVPVA/0.15. 
An increase in the b* value can be seen for both 
increasing temperatures and increasing residence times. 
This is caused by an increasing thermal and mechanical 
stress resulting in material decomposition and thus a 
yellow or brown discoloration of the ASDs. Similar 
trends were also obtained for the other formulation 
ITR/PVPVA as well as for any drug weight fraction 
(data not shown). 
CONCLUSIONS 
A special UV-Vis probe, which measures low material 
quantities inside the small scale extruder, was integrated 
into the process. Based on a comparison with an optical 
inspection of the extrudates, the suitability of the in-line 
UV-Vis spectroscopy was confirmed. With the 
transmission spectra and the lightness value L*, 
remaining crystalline components were detected and 
thus the formation of ASDs could be assessed. Since 
color values were also determined, conclusions 
regarding the material decomposition were drawn.  
The influence of temperature and residence time on the 
formation of ASDs was quantified. By comparing the 
temperature required for dissolution with the 
temperature of decomposition for a specific API content 
and residence time, suitable process regimes can be 
identified to finally optimize the whole process 
development. 
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ABSTRACT 
Two-phase biocatalysis is commonly used for the bioconversion of water-insoluble chemical and pharmaceutical 
compounds. In research laboratories, such processes often take place in flasks and are driven and limited by slow diffusive 
processes. In this work, we developed droplet-based microfluidic systems and used them to perform testosterone 
dehydrogenation. The use of microdroplets as reaction vessels offers the advantage of greatly improved diffusion rates 
due to significantly increased surface-to-volume ratio. We found that indeed reaction time was reduced from tens of 
minutes to tens of seconds without sacrificing conversion efficiency. This demonstrates the potential of droplet-based 
two-phase biocatalysis. 
Keywords: two-phase biocatalysis, microdroplets 
INTRODUCTION 
In biocatalysis, enzymes or whole cells are used as catalysts 
for chemical transformations. Compared to chemical 
methods, biocatalysis offers several advantages such as 
high specificity, environmental friendliness, and reduced 
energy requirements due to reactions at room temperature 
and atmospheric pressure [Anthonsen, 2000; Faber, 2011]. 
Enzymes used as catalysts for chemical reactions are 
generally less stable in organic media compared to their 
natural aqueous environment, but chemical and 
pharmaceutical compounds are often insoluble in water 
[Klibanov, 2001]. The use of aqueous/organic two-phase 
systems provides a solution to this problem. Such two-
phase systems are now commonly used in multiple 
biotransformations [Adebar, 2019]. The addition of a non-
polar organic phase as a substrate reservoir and product 
sink can ensure high substrate loadings while avoiding 
enzyme inhibition or inactivation. 
Figure 1 shows a simplified example of a traditional 
aqueous/organic two-phase system. In this configuration, 
biocatalysis is driven by diffusion. The substrate diffuses 
into the aqueous phase, where it is converted by the 
enzyme. In turn, the product diffuses back into the organic 
phase, where it is 
collected. Diffusion 
is often facilitated 
by shaking the 
flasks or stirring 
their contents. 
Mixing increases 
the contact area 
between the two 
phases, but at the 
same time 
mechanical stress 
associated with shaking or stirring can cause enzyme 
denaturation. The formation of emulsions during stirring is 
also a limitation of such systems, as phases are difficult to 
separate for product collection. Additionally, the amount or 
type of organic phase can also have an inhibitory effect on 
the reaction, as it can impede enzyme activity. 
RESEARCH CONCEPT 
In this work, we designed, fabricated, and tested 
microfluidic devices for droplet-based two-phase 
biocatalysis on-chip. The use of microfluidic droplets as 




miniaturized reactors offers the advantage of greatly 
improved diffusion rates due to the significantly increased 
surface-to-volume ratio [Žnidaršič-Plazl, 2014; Fernandes, 
2010]. In turn, higher diffusion rates can increase the 
reaction conversion rate. Another advantage of 
microfluidic droplets is lack of mechanical stress 
associated with their formation and their relative ease of 
separation compared to emulsions created by active mixing 
in flasks. Microdroplet separation ensures efficient product 
extraction. 
ENZYME-BASED BIOCATALYTIC REACTION 
17β-Hydroxysteroid dehydrogenases (17β-HSDs) are a 
type of NAD(P)-dependent oxidoreductases. Their main 
function is to participate in the metabolism of sex hormones 
by controlling the last step in the formation of androgens 
and estrogens. Thus, they play an important role in 
reproduction [Oppermann, 1996; Benach, 1996]. Herein, 
17β-hydroxysteroid dehydrogenase is used for testosterone 
dehydrogenation to androstenedione, as shown in Figure 2 
below. 
Androstenedione can be used as a precursor of hormones, 
such as male hormones and protein synthesis hormones, 
and can be used to synthesize pharmaceuticals such as 
spironolactone, hydrocortisone, prednisone oxide, and 
dexamethasone [Elks, 2014]. Testosterone is the main 
protein assimilation substance, and it is of great 
significance to health, affecting, among others, sexual 
desire, strength, and immune function [Mooradian, 1987]. 
MICROFLUIDIC DEVICE DESIGN AND 
FABRICATION  
There are three typical microfluidic device architectures 
used to generate droplets: T-junctions, flow-focusing 
devices, and co-flowing devices [i Solvas, 2011]. The 
experiments described in this work were carried out in 
flow-focusing devices.  
The droplets produced have an oil-in-water (O/W) 
structure. The continuous phase is a buffer containing the 
enzyme, and the discrete phase is an organic solvent 
containing the substrate testosterone. Figure 3 shows the 
geometry of the microfluidic device used in this study. To 
generate droplets, the continuous phase "squeezes" the 
fluid front of the dispersed phase from both sides of the 
intersection, and uses the "neck" structure of the channel 
downstream of the liquid front to form discrete droplets. 
The width of the continuous-phase microchannel, 𝑤𝑐𝑜𝑛, is
110 μm and the width of the discrete-phase microchannel, 
𝑤𝑑𝑖, is 60 μm. The two phases converge in a narrow "neck"
with a width of 50 μm and form droplets in a 400 μm 
channel.  
The microfluidic devices were fabricated in glass using 
femtosecond laser ablation. Glass was chosen due to its 
chemical inertness, which ensures no effects on the 
biocatalytic reaction. After laser ablation of microchannels, 
the glass wafer with a thickness of 700 nm was etched in 
hydrofluoric acid to remove surface defects, followed by 
cleaning in piranha solution (a mixture of sulfuric acid, 
water, and hydrogen peroxide), accompanied by an 
increase in surface hydrophilicity. To seal the microfluidic 
channels, the base wafer was thermally bonded to a cover 
glass wafer. The finished microfluidic device was therefore 
made exclusively out of transparent glass, which also 
allows the use of microscopy for process monitoring. 
Figure 2: Conversion of testosterone to 
androstenedione catalyzed by 17β-hydroxysteroid 
dehydrogenase. 





The aqueous phase and organic phase solutions were 
prepared before the start of the experiment. 50 µl of a 10 
µg/µl enzyme solution, 1000 µl of 20 mM nicotinamide 
adenine dinucleotide (NAD+) and 3450 µl of buffer were 
mixed to form the aqueous phase. The buffer was 
composed of 20 mM Tris-HCl and 25 mM sodium chloride 
at pH 9. Methyl tertiary butyl ether (MTBE) was chosen as 
the organic solvent, in which the concentration of 
testosterone was 10 mM. In addition, 1% Tween 20 was 
added to the aqueous phase as a surfactant to reduce the 
surface tension and promote the formation and stabilization 
of the droplets.  
CONTINUOUS BIOCATALYTIC REACTIONS IN 
MICRODROPLETS 
Syringe pumps were used to push the organic and aqueous 
phase into microchannels, and experiments were carried 
out at two flow rates. In sample 1, the flow rate of the 
organic phase was 1.5 µl/min, and the flow rate of the 
aqueous phase was 4.5 µl/min. In sample 2, the flow rates 
of the organic and aqueous phases were 3 µl/min and 9 
µl/min, respectively. At the outlet of the microfluidic 
system 250 µl of liquid was collected for analysis. Ethyl 
acetate was added to the collection container at a ratio of 
1:1 (ethyl acetate to reaction solution) to terminate the 
reaction. In addition, a 6 cm-long PTFE tube with an inner 
diameter of 0.25 mm was installed at the outlet of the glass 
microfluidic chip to provide a longer residence time for the 
reaction. The residence time (i.e. reaction time) of the 
reaction solution in the system was approximately 40 s 
(sample 1) and 20 s (sample 2). 
The droplets generated in the microchannel are shown in 
Figure 4. The average droplet diameter was approximately 
80 μm. 
RESULTS AND DISCUSSION 
High performance liquid chromatography (HPLC) was 
used for the detection of substrate and product in the 
solution. Figure 5 below shows the chromatogram of the 
reaction in sample 1. By calculating the ratio of the peak 
areas of the product and the substrate, the conversion of the 
substrate testosterone to the product androstenedione in the 
two reactions was determined as follows: sample 1: 91%, 
sample 2: 85%. The corresponding amount of the produced 
product were 0.5687 µmol and 0,53125 µmol, respectively. 
The same experiment was performed in a conventional 
batch reaction at the same substrate concentration of 10 
mM and stirring at 900 rpm. The concentration of enzyme 
in the buffer was 50 µg/ml. As using large amounts of 
organic solvent can affect the activity of the enzyme, the 
ratio of the organic to aqueous phase used was 1:9. At a 
reaction time of 10 minutes, the conversion rate was 85 %. 
After 15 minutes, the conversion rate increased to 93 %. 
CONCLUSIONS 
The dehydrogenation reaction of testosterone catalyzed by 
17β-HSD was realized in microdroplets and was compared 
to traditional batch experiments. We found that high 
conversion rates can be achieved in such miniaturized 
systems in significantly less time (tens of seconds) 
compared to the traditional setup (tens of minutes).  This is 
partially due to much higher diffusion rates achieved in 
microsystems facilitated by the large droplet surface-to-
volume areas. Therefore, such miniaturized reactors are a 
promising platform for the performance of two-phase 
biocatalysis. 
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